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ABSTRACT 
Motor neuron diseases preferentially affect specific neuronal populations with distinct clinical 
features even if disease-causing genes are expressed in many cell types. In spinal muscular 
atrophy (SMA), somatic motor neurons are selectively vulnerable to a deficiency in the 
broadly expressed survival of motor neuron 1 (SMN1) gene. In amyotrophic lateral sclerosis 
(ALS), mutations in multiple ubiquitously expressed genes have been identified that result in 
the same selective vulnerability. However, certain somatic motor neuron groups, including 
oculomotor and trochlear (CN3/4) neurons, are for unknown reasons relatively resistant to 
degeneration. We hypothesized that we could use CN3/4 motor neuron resistance as a tool to 
dissect mechanisms of vulnerability and protection, which would aid in identifying drug 
targets for the treatment of so far incurable motor neuron diseases. 
Within this thesis work, we developed a robust method for spatial transcriptomic 
profiling of closely related neuronal populations that is sensitive down to single cells and can 
be applied to partly degraded human post-mortem tissues. We called this method LCM-seq 
(laser capture microscopy coupled with RNA sequencing). We applied LCM-seq to reveal 
longitudinal changes in gene expression in a mouse model of SMA in order to elucidate 
distinct adaptation mechanisms of several motor neuron populations that could account for 
their differential susceptibility. We revealed a common activation of DNA damage response 
and apoptosis pathways in somatic motor neurons independent of their susceptibility. We 
furthermore found gene expression changes that were preferential to the resistant CN3/4 
motor neurons. Of particular interest were genes that function in regeneration, synaptic 
vesicle release and those that protect cells from oxidative stress and apoptosis. We speculate 
that these genes could play a role in the resistance of CN3/4 motor neurons and their 
manipulation in vulnerable motor neurons could be used to protect these from degeneration. 
As proof of concept, we further investigated candidates with implications for differential 
vulnerability that we had previously identified in a transcriptome analysis in the normal rat. 
We demonstrated a relative conservation across species by confirming the expression patterns 
of multiple proteins in mouse and human and in health and disease. Moreover, we provided 
functional evidence that the oculomotor restricted insulin-like growth factor 2 (IGF-2) can 
rescue vulnerable spinal motor neurons in in vitro and in vivo models of ALS. This indicates 
that IGF-2 could in part play a role in the preservation of CN3/4 motor neurons in ALS. By 
combining comprehensive studies in mouse models and the use of human ALS patient tissues 
as well as patient-derived induced pluripotent stem cell based in vitro assays we could 
maximize the chance of identifying mechanisms with relevance in human disease. 
In conclusion, we provide a tool box for transcriptional profiling of neuronal populations with 
differential vulnerability followed by functional studies in mouse and human aiding in 
elucidating pathological mechanisms in neurodegenerative diseases, which could lead to the 
identification of drug targets for the treatment of motor neuron diseases. 
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1 INTRODUCTION 
Motor neuron diseases (MNDs) are characterized by the selective loss of somatic motor 
neurons that innervate skeletal muscle and control voluntary movements. Accompanied by 
massive muscle wasting leading to paralysis, these diseases are severely debilitating and 
mostly lethal. Death usually occurs due to respiratory failure and so far, there are no cures for 
any MNDs. 
1.1 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset MND with one to three 
new cases per year in a population of 100,000. Onset of ALS typically occurs between 46 and 
63 years of age and patients die on average between three and five years after diagnosis. 
Motor neurons originating in the cerebral cortex, brainstem, and spinal cord are affected in 
ALS. More specifically, limb-, trunk-, and diaphragm- innervating spinal motor neurons, 
hypoglossal motor neurons innervating tongue and esophagus, facial and trigeminal motor 
neurons, which control mimics and mastication, respectively, degenerate. 
The majority of ALS cases appear sporadic (90-95%, sALS), whereas 5-10% are 
clearly inherited (familial ALS, fALS). More than 50 sALS- and fALS- associated genes 
have been identified so far, all of them being broadly expressed throughout many tissues. 
Among them are genes that function in several aspects of RNA metabolism, protein 
homeostasis and quality control, and cytoskeletal organization. The most commonly mutated 
gene in ALS (found in 25% of the familial and 10% of sporadic cases) is the recently 
identified C9ORF72 (DeJesus-Hernandez et al. 2011; Renton et al. 2011), the exact function 
of which is still unclear. Among the most prevalent genes implicated in RNA dysregulation 
are the TAR DNA-binding protein (TARDBP, TDP-43) (Gitcho et al. 2008; Sreedharan et al. 
2008; Kabashi et al. 2008) and fused in sarcoma (FUS) (Kwiatkowski et al. 2009; Vance et 
al. 2009), causing around 5% of fALS and less than 1% of sporadic cases each. Another 
important ‘ALS gene’ is superoxide dismutase 1 (SOD1), which is responsible for around 
20% of familial cases and 3-7% of sALS cases. Mutated SOD1 was the first ALS-causing 
gene identified in the early nineties (Rosen et al. 1993) and much of the knowledge about 
disease mechanisms originates from studies in mutant SOD1 transgenic mouse models of 
ALS, which will be discussed later. 
1.1.1 Disease mechanisms and genetics in ALS 
Independent of the etiology of the disease, deregulation of many cellular processes can be 
observed but what is cause and effect remains mostly unclear. Oxidative stress, mitochondrial 
dysfunction, excitotoxicity, ubiquitin and proteasome dysfunction, activation of inflammatory 
and apoptosis pathways, RNA metabolism deficits, DNA damage and cytoskeletal 
abnormalities including axonal transport defects (Figure 1.1) have been observed in fALS as 
well as sALS (reviewed in Ferraiuolo et al. 2011; Taylor et al. 2016). Currently, the only 
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approved drug for the treatment of ALS is Riluzole, which, among other not fully elucidated 
functions, inhibits presynaptic glutamate release and thus reduces excitotoxicity. 
Excitotoxicity is just one of many disease mechanisms in ALS and thus it is not surprising 
that Riluzole elicits only moderately beneficial effects, extending the lifespan of patients by a 
few months only (Miller et al. 2012). 
 
Figure 1.1. Many cellular processes are disturbed in ALS. (a) The protein quality control can be 
compromised in ALS. Mutations in autophagy genes (e.g. UBQLN2, OPTN and TBK1) are 
responsible for familial as well as sporadic ALS cases and mutations in SOD1 lead to misfolding and 
aggregation of the protein. Endoplasmatic reticulum (ER) stress is a common feature in ALS motor 
neurons. Glial cells are major contributors with (b) microglia releasing inflammatory cytokines, (c) a 
lack of metabolic support from oligodendrocytes and (d) astrocytes secreting toxic soluble factors as 
well as exacerbating excitotoxicity due to decreased uptake of excitatory neurotransmitters. (e) 
Cytoskeletal defects and altered axonal transport are a common and early feature of ALS. Furthermore, 
mutations in the gene encoding a tubulin subunit TUBA4A, in PFN1, an actin binding protein, and in 
DCTN1, a component of the dynein motor complex, can cause ALS. (f) Multiple aspects of RNA 
metabolism are deregulated and mutations in several RNA binding proteins can cause ALS, such as 
FUS, TDP-43, HNRNPA1, ANG and MATR3. Reprinted by permission from Macmillan Publishers 
Ltd: [NATURE] (Taylor et al. 2016), copyright (2016), license number 4053710699392. (Font size 
was adjusted to improve legibility). 
Protein aggregations are a hallmark feature of ALS that can be manifested in ubiquitinated 
cytoplasmic inclusions of several different proteins like SOD1, FUS and TDP-43. SOD1 is a 
cytoplasmic enzyme that converts harmful superoxide radicals to oxygen and hydrogen 
peroxide. Multiple mutations in the SOD1 gene have thus far been identified to cause ALS, 
most of which confer conformational instability of the protein resulting in its aggregation but 
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also the formation of soluble oligomers. The molecular basis of how mutated SOD1 exerts its 
toxicity are not completely understood, however, a toxic-gain-of function is likely. Increased 
oxidative stress, mitochondrial dysfunction, defects in axonal transport, autophagy 
dysregulation and endoplasmatic reticulum (ER) stress have been linked to SOD1 mutations. 
Both DNA/RNA- binding proteins FUS and TDP-43 play roles in transcription, splicing and 
micro RNA processing and mainly locate to the nucleus under normal physiological 
conditions. Both proteins target thousands of RNAs (Polymenidou et al. 2011; Tollervey et 
al. 2011; Lagier-Tourenne et al. 2012) and altered function of either FUS or TDP-43 may 
have broad consequences. A loss of its nuclear function is thought to be a major disease-
causing mechanism for TDP-43 (Walker et al. 2015). However, a toxic gain-of-function 
cannot be excluded as contributor to disease pathology (Guerrero et al. 2016). Cytoplasmic 
TDP-43 containing inclusions can be found in the majority of both sporadic and familial ALS 
(except for SOD1 and FUS cases), suggesting a more general role in ALS pathology trough 
either loss- or toxic gain-of-function. As pathology occurs irrespective of normal FUS in the 
nucleus, mutations in this gene likely lead to a toxic gain-of-function (Mitchell et al. 2013; 
Sharma et al. 2016; Sun et al. 2015). At the same time, a loss-of-function mechanism also in 
FUS- ALS cannot be excluded as contributing to disease pathology: depletion of both FUS 
and TDP-43 results in transcription associated DNA damage in vitro (Hill et al. 2016). 
Activation of the DNA damage response can lead to apoptosis and it will be interesting to 
reveal if DNA damage is an early event in ALS pathology. 
There is no consensus yet on the underlying mechanism also in C9ORF72-related 
ALS. ALS-causing C9ORF72 presents with a vast hexanucleotide repeat expansion that 
results in the sequestration of RNA and proteins (RNA foci (DeJesus-Hernandez et al. 2011)) 
and the presence of dipeptide repeat proteins (DPRs) through repeat-associated non-ATG 
dependent translation (Mori et al. 2013). RNA foci might sequester RNA binding proteins 
and thus lead to dysregulation of several biological processes. Even though its function is not 
clear, there is emerging evidence for a role of C9ORF72 in nuclear import/export (Jovičić et 
al. 2015; Zhang et al. 2015; Freibaum et al. 2015), which is in line with the presence of TDP-
43 positive cytoplasmic inclusions in C9ORF72 patients. More recently, DPRs have been 
linked to the mislocalization of TDP-43 (Khosravi et al. 2016). At the same time, decreased 
levels of normal C9ORF72 protein have been reported in patients (Waite et al. 2014) raising 
the possibility of additional loss-of-function mechanisms in C9ORF72-related ALS. 
However, the finding that neural depletion of C9orf72 in mice does not produce a motor 
phenotype or altered survival suggest that loss-of-function alone is not a disease-causing 
mechanism (Koppers et al. 2015). 
1.2 Spinal muscular atrophy 
A different form of MND, with an incidence of 1/6000-1/10,000 live births and a carrier 
frequency of 1 in 50, is spinal muscular atrophy (SMA). SMA is the most common genetic 
cause of infant death and children with the most severe forms of SMA do not live past their 
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second year of life. Depending on the age of onset and the maximum motor function achieved 
by the patients, SMA is typically categorized into five types: type I-IV, with the most 
common and severe form being type I, and type IV being an adult-onset, non-lethal form. 
Extremely severe cases, where death occurs before 6 months of age, are classified as type 0 
SMA. In SMA, predominantly motor neurons in the anterior horn of the spinal cord are 
affected. However, an increasing number of studies report the involvement of brainstem 
motor nuclei, such as the facial or hypoglossal nucleus (Harding et al. 2015; Petit et al. 2011; 
Rudnik-Schöneborn et al. 2009). 
In contrast to ALS, which can be caused by mutations in one of many different genes, SMA 
is a monogenetic disease. In more than 95% of the cases, SMA is caused by homozygous 
deletions or mutations in the survival of motor neuron (SMN) 1 gene (Bussaglia et al. 1995; 
Lefebvre et al. 1995). The SMN protein is ubiquitously expressed and has functions in 
multiple aspects of RNA processing (reviewed in Singh et al. 2017). The complete loss of 
functional SMN protein is embryonically lethal (Schrank et al. 1997). Owing to a gene 
duplication that is almost exclusive to humans, this loss can be compensated for by the 
expression of the nearly identical paralogue gene SMN2 (Monani et al. 2000). However, one 
base pair transition leads to exon 7 skipping in around 90% of the transcripts, thus resulting in 
a truncated form of the SMN protein, which is less stable (Monani et al. 1999). Humans 
possess a variable number of SMN2 copies. A higher SMN2 copy number can either prevent 
SMA completely or lead to a less severe form of the disease (Monani et al. 2000; Taylor et al. 
1998). Increasing exon 7 inclusion in transcripts from the SMN2 gene presents a most 
promising therapeutic strategy and encouragingly, positive outcomes in phase I and II clinical 
trials have already been reported (Chiriboga et al. 2016; Finkel et al. 2017). 
1.2.1 SMA disease mechanisms: SMN- one gene, many functions 
Several of the disease mechanisms that occur in ALS have also been described in SMA, such 
as mitochondrial abnormalities (Acsadi et al. 2009; Miller et al. 2016), oxidative and ER 
stress (Ng et al. 2015), neuroinflammation (Rindt et al. 2015), axonal transport defects and in 
particular RNA metabolism related disturbances. Due to the multifaceted function of SMN at 
several stages in RNA processing and additional functions, also here the exact mechanism(s) 
by which low levels of SMN result in SMA remains elusive. 
The most studied function of the SMN protein is its role in the assembly of small 
nuclear ribonucleoproteins (snRNPs), essential components of the spliceosome. Several 
studies have correlated snRNP assembly activity with disease severity (Wan et al. 2005; 
Gabanella et al. 2007). A role for splicing defects in SMA is underlined by the finding that 
splicing alterations were identified in several models of SMA (Zhang et al. 2008; Bäumer et 
al. 2009; Zhang et al. 2013; Doktor et al. 2016). These alterations are not restricted to affected 
tissues, however, and it remains unclear to what extent dysregulation of splicing contributes 
to motor neuron pathology. Furthermore, there is no consensus about the timing of splicing 
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alterations (pre-symptomatic versus late-symptomatic changes) (Bäumer et al. 2009; Zhang et 
al. 2013) and thus neither on a causal or effective nature of splicing disturbances. 
SMN may have tissue but also cell compartment specific functions and the detection 
of its presence in neuronal processes was quickly followed by studies investigating an axonal 
specific role (Jablonka et al. 2001; Fan and Simard 2002). Here, SMN functions in messenger 
ribonucleoprotein (mRNP) assembly for the axonal transport of transcripts including β-actin 
(ACTB) and GAP43 mRNA (Rossoll et al. 2003; Fallini et al. 2010, 2016). Given that the 
neuromuscular junction (NMJ) is an early target in the pathology of SMA as evidenced by 
neurofilament accumulation at the presynaptic terminal (Cifuentes-Diaz et al. 2002), the 
function of SMN in axonal trafficking is a likely early contributor to disease. Furthermore, 
the lack of SMN-binding to the actin associated protein profilin 2 (PFN2) contributes to 
impaired neurite outgrowth (Bowerman et al. 2007) and implies yet another function for the 
SMN protein in cytoskeletal dynamics. 
Apart from snRNP and mRNP assembly, SMN has been proposed to serve roles in 
many aspects of RNA processing, including transcription, translation and histone mRNA 
modification (Singh et al. 2017). A direct interaction of SMA with RNA polymerase II has 
already been described in 2001 (Pellizzoni et al. 2001) and recently a role for SMN in the R-
loop resolution pathway for transcription termination has been suggested (Zhao et al. 2015). 
Due to the diverse functions of the SMA-causing gene it still remains challenging to pinpoint 
the disease-causing mechanism(s). Most likely it is a combination of the lack of different 
functions that contributes to the overall pathology seen in SMA. While motor neurons appear 
to be the primarily affected cell type, disruption in other tissues is clearly evident (reviewed 
in Hamilton and Gillingwater 2013). Different tissues likely not only depend on different 
levels of SMN (Kariya et al. 2014) but also on different functions. To understand the 
susceptibility specifically of motor neurons, comparisons to other motor neuron diseases are a 
promising strategy. 
1.3 Where do ALS and SMA meet? 
The shared motor neuron pathology and continuously increasing overlap in disease 
mechanisms revealed between ALS and SMA make cross disease comparisons an attractive 
approach to understand selective vulnerability in MNDs. Interestingly, FUS can directly 
interact with SMN and mutations in FUS (that cause ALS) result in dysregulation of SMN as 
shown by nuclear gem depletion (of which SMN is a major component (Liu and Dreyfuss 
1996)) (Sun et al. 2015) as well as altered axonal localization of the protein (Groen et al. 
2013). Overexpression of SMN in TDP-43 ALS mice had beneficial effects on motor neuron 
preservation (Perera et al. 2016). Furthermore, yet another DNA/RNA binding protein has 
recently been associated with motor neuron disease. Two groups independently demonstrated 
that genetic depletion of the zinc finger protein Zfp106 (Zfp106-/-) in mice results in a 
 6 
profound neuromuscular phenotype with motor neuron degeneration (Joyce et al. 2016; 
Anderson et al. 2016).  
Taken together, the fact that several DNA/RNA binding proteins are associated with motor 
neuron diseases and DNA damage and alterations in RNA metabolism can have widespread 
consequences makes these mechanisms interesting targets for further investigation in the 
context of motor neuron susceptibility. 
1.4 Differential vulnerability in motor neuron disease 
As mentioned above, all of the known MND-causing genes are widely expressed in most 
tissues and cell types throughout the body but somatic motor neurons appear particularly 
vulnerable to these toxic genetic changes. Interestingly, there are striking differences in 
susceptibility between subtypes of somatic motor neurons. The reasons for this selective and 
differential vulnerability, however, are poorly understood. Among the relatively resistant 
populations, in both ALS and SMA, are the motor neurons of the oculomotor (CN3), 
trochlear (CN4) and abducens (CN6) nuclei (Gizzi et al. 1992), which control eye movements 
within the ocular motor system. Sparing of these cells enables the use of eye tracking devices 
as means of communication and navigation for patients that have otherwise lost the ability to 
move and speak (Kubota et al. 2000; Caligari et al. 2013). 
1.4.1 Preservation of the ocular motor system 
In both ALS and SMA, changes at the interface of neuron and muscle, the neuromuscular 
junction (NMJ), are early features of disease pathology. Defects in axonal transport occur in 
ALS before an overt phenotype can be seen (Bilsland et al. 2010), whereas NF accumulation 
and impaired neurotransmitter release can be observed at the NMJs of pre-symptomatic SMA 
mice (Ruiz and Tabares 2014; Kariya et al. 2008; Cifuentes-Diaz et al. 2002). In ALS, 
retraction of axons from muscle endplates occurs before a pronounced loss of motor neuron 
somas (‘dying back’ pattern (Fischer et al. 2004)). Muscles innervated by vulnerable motor 
neurons, including diaphragm and limb muscles show profound pathology already at early 
symptomatic stages, while NMJs in the extraocular muscles of SODG93A mice are preserved 
even at disease end-stage (Tjust et al. 2012; Valdez et al. 2012). This is consistent with 
findings in human post-mortem tissues, where extraocular muscles were substantially 
preserved compared to limb muscles of the same end-stage patients (Ahmadi et al. 2010). 
Comley et al. confirmed the persisting integrity of extraocular NMJs also in an SMA mouse 
model (Comley et al. 2016). In line with these findings, motor neuron counts were decreased 
in a number of vulnerable brainstem nuclei, in contrast to oculomotor neurons that were 
unchanged at disease end-stage in SOD1 and TDP-43 mouse models of ALS (Haenggeli and 
Kato 2002; Ferrucci et al. 2010; Spiller et al. 2016). The ocular motor system has a number of 
unique characteristics and several groups are trying to pinpoint which of these could explain 
its resistance. The transcriptome of CN3/4 motor neurons for example differs significantly 
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from other motor neuron populations as shown in rat, mouse, and man (Hedlund et al. 2010; 
Kaplan et al. 2014; Brockington et al. 2013). 
1.4.2 Physiological properties of differentially vulnerable motor neurons 
Differences in electrophysiological properties, like firing rate and input resistance of neuronal 
populations have been proposed to account for differential susceptibility among motor 
neurons. In ALS, fast firing (FF) motor neurons degenerate before fatigue resistant (FR) and 
slow (S) motor neurons (Frey et al. 2000; Hadzipasic et al. 2014; Pun et al. 2006). Relatively 
resistant S motor neurons have smaller dendritic trees (Cullheim et al. 1987) and thus a 
smaller membrane surface compared to FF and FR motor neurons. Hence, the input 
resistance of S motor neurons is lower resulting in higher excitability. In line with that, 
resistant CN3 neurons are more excitable than spinal motor neurons due to a higher resting 
membrane potential (Braughler and Hall 1982; Torres-Torrelo et al. 2012). In SMA, 
however, the comparison of NMJ pathology of muscles innervated by FF, FR, and S motor 
neurons revealed no correlation of motor neuron type and susceptibility to denervation 
(Murray et al. 2010, 2008). Thus, it is rather unlikely that the electrophysiological properties 
of CN3/4 motor neurons are solely underlying their resistance in all MNDs. 
The same studies revealed differences in the survival of motor neurons that innervate 
muscles, which are in close proximity to each other. Consequently, also axon length can be 
ruled out as a key factor for susceptibility in MNDs. 
To date, it is unclear why some motor neurons are more resistant to degeneration than others. 
Understanding the underlying basis for resistance and vulnerability could provide the basis 
for identifying drug targets for the treatment of MNDs. 
1.5 Cell autonomous and non-cell autonomous mechanisms in motor neuron disease 
As MND-causing genes are broadly expressed it appears fundamental to ask to what extent 
other cell types than the primarily affected ones play a role in disease. 
1.5.1 Glia in motor neuron disease 
Astrogliosis and microglial activation are hallmark features of ALS with reactive astrocytes 
and microglia surrounding degenerating motor neurons in ALS patients as well as mouse 
models (Hall et al. 1998; Perera et al. 2016; Henkel et al. 2004; Schiffer et al. 1996). 
Increased astrocyte activation has also been observed in SMA patients and mice (Rindt et al. 
2015), and iPSC-derived SMA astrocytes display morphological abnormalities and altered 
calcium homeostasis (Rindt et al. 2015; Zhou et al. 2016). Mutant SOD1 astrocytes release 
inflammatory factors like prostaglandin E2, leukotriene B4 and nitric oxide (Hensley et al. 
2006). Their important role in clearing excess excitatory neurotransmitters is compromised 
by the down-regulation of excitatory amino acid transporter 2 (EAAT2) thus contributing to 
excitotoxicity (Rothstein et al. 1995) (Figure 1.1d). Microglia appear to have an initially 
 8 
protective function, whereas disease is later exacerbated by the release of cytokines from 
these cells (Zhao et al. 2013) (Figure 1.1b). Interestingly, microglia and astrocytes display 
markedly lower levels of activation around the resistant CN3 motor neurons at symptomatic 
and end-stages in SOD1 mice (An et al. 2014, and personal observation). Finally, important 
metabolic support for motor neurons from oligodendrocytes is lacking due to oligodendrocyte 
degeneration (Kang et al. 2013) and the downregulation of MCT1 lactate transporters 
(Figure 1.1c). 
Studies using the selective manipulation of disease-causing genes in distinct cell types 
in ALS and SMA mouse models have gained us important insight on the role of glia in 
disease (Boillée et al. 2006; Kang et al. 2013; Yamanaka et al. 2008; McGovern et al. 2015; 
Kariya et al. 2008; Martinez et al. 2012). These reports suggest a strong impact of glial cells 
like astrocytes and microglia on disease progression. Initiation of degeneration, however, 
seems to come from within motor neurons and in ALS also from oligodendrocytes. Removal 
of mutant SOD1 from motor neurons resulted in significantly delayed onset of the disease and 
early disease progression, whereas its selective depletion in microglia or astrocytes slowed 
disease progression substantially. While oligodendrocytes appear to be unaffected by low 
levels of SMN (O’Meara et al. 2017), restoration of normal SMN levels in Schwann cells can 
rescue peripheral myelination defects and improve NMJ pathology (Hunter et al. 2013). 
Survival, however, remains unaltered in these mice. 
In general, simultaneous manipulation of the disease-causing gene in motor neurons and glia 
leads to a more pronounced effect on phenotype than targeting motor neurons alone. Thus, 
therapeutic intervention targeting glia presents a promising strategy to slow disease 
progression. This is exemplified by Mastinib and Ibudilast both of which reduce microglia 
secreted inflammatory factors. Mastinib was shown to slow disease progression in a SOD1 
rat model of ALS even when administered after onset of paralysis through ameliorating 
neuroinflammation (Trias et al. 2016). Ibudilast has been used for more than two decades for 
the treatment of asthma. Its neuroprotective effect in vitro from cell death induced by 
microglia (Mizuno et al. 2004) gives hope for the treatment of neurodegenerative diseases. 
Both of these compounds are currently in phase II clinical trials in ALS 
(https://clinicaltrials.gov/). 
1.5.2 Muscle in motor neuron disease 
The relationship of muscle and motor neurons is characterized by communication into both 
directions. The extent to which the postsynaptic muscle is a driver of disease in ALS is highly 
debated. Also here, selective expression or depletion of mutant genes in muscle was used to 
assess the extent of the resulting motor phenotype. Miller et al. (2006) found functional 
improvement in mice where mutant SOD1 was reduced in both motor neurons and muscle, 
whereas muscle-restricted reduction of mutant SOD1 protein (by 25% to 50% using two 
different strategies) had no beneficial effects. These findings indicate that either muscle is not 
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a driver of motor neuron degeneration in ALS, or that the reduction of mutant protein 
achieved was not sufficient to rescue the phenotype. Another study selectively overexpressed 
mutant SOD1 in muscle, which resulted in muscle atrophy while motor neuron numbers were 
unaltered (Dobrowolny et al. 2008), rendering it unlikely that muscle is a systemic driver of 
disease. In contrast, the study by Wong and Martin (2010) demonstrated a severe motor 
phenotype including motor neuron degeneration when overexpressing mutant or wild-type 
SOD1 in muscle. These opposing findings can likely be attributed to the different strategies 
that were used to drive muscle-specific expression in these studies (lentiviral delivery directly 
to muscle by Miller versus use of the α-actin promoter by Wong and Martin) and further 
investigation is necessary to draw stronger conclusions as to what extent muscle is involved 
in the pathology of ALS.  
To study the role of muscle in SMA, Cifuentes-Diaz et al. (2001) performed muscle selective 
Smn- depletion using the human skeletal actin (HSA) promoter and reported reduced survival 
of these animals. As mentioned above, complete depletion of SMN is embryonically lethal. 
These mice did not harbor any human SMN2 transgene and the complete absence of SMN 
protein in muscle could therefore account for the disease phenotype. In support, restoration of 
SMN levels selectively in muscle on an SMA background (using the same promoter) did not 
result in increased life-span of the animals and neither was motor function improved. 
However, expression driven by the HSA promoter does not affect SMN expression in satellite 
cells. Satellite cells are skeletal muscle precursor cells that are responsible for muscle growth 
during early postnatal development. They are maintained in adulthood and are the basis for 
the massive regenerative capacity of muscle. Selective restoration of SMN in muscle 
progenitors with the Myf5 promoter led to normal muscle fiber growth and moderately 
extended survival (Martinez et al. 2012). However, no phenotypic improvement at the NMJ 
could be detected. In contrast to muscle specific restoration, selective normalization of SMN 
levels in motor neurons in the same study rescued transmission at the NMJ with only partial 
improvement of muscle fiber growth and a comparable increase in survival. Two studies that 
were co-published by the same lab (Iyer et al. 2015; McGovern et al. 2015) came to similar 
results demonstrating that muscle specific restoration or depletion did not affect survival, 
while normal SMN levels in motor neurons, even though survival effects were minimal, 
rescued electrophysiological deficits in SMA mice. The best results were achieved when 
restoring SMN levels through a nestin promoter, which drives expression in various precursor 
cells in the central nervous system, underlining the contribution of glia and other neuronal 
populations in the pathology of SMA. 
1.5.3 Motor neuron intrinsic vulnerability 
Selective introduction of disease-causing mutations in motor neurons on a normal 
background or selective restoration on a mutant background do have profound effects on 
motor neuron survival and/or motor function. Moreover, several in vitro studies show clear 
evidence that mutant motor neurons are less viable and more susceptible to mutant astrocyte-
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mediated toxicity compared to wild-type motor neurons (Corti et al. 2012; Sareen et al. 2012; 
Di Giorgio et al. 2007; Ebert et al. 2009; Kiskinis et al. 2014; Nagai et al. 2007). It is 
therefore crucial to elucidate motor neuron intrinsic mechanisms in order to understand their 
selective vulnerability in MNDs. 
1.6 Models of motor neuron disease 
From electrophysiological measurements in motor neuron disease patients, analysis of human 
post-mortem tissues, and whole genome sequencing we have gained much insight into the 
underlying pathology and genetics in MNDs. Most of the knowledge on cellular and 
molecular disease mechanisms originate from studies that use animal or in vitro models of 
MNDs. ALS and SMA are successfully studied in models as diverse as zebrafish, drosophila, 
C. elegans, and yeast (reviewed in Edens et al. 2015; Patten et al. 2014; Tenreiro et al. 2013; 
Matsumoto et al. 2004). As the model systems used in this thesis are mouse models and stem 
cell-derived motor neurons, these will be discussed in more detail here. 
1.6.1 ALS mouse models 
Mutations in the SOD1 gene were the first identified genetic cause of ALS (Rosen et al. 
1993), which led to the fast development of rodent ALS models. SOD1 knockout or 
expression of transgenes harboring mutations that reduce SOD1 activity in mice fail to induce 
a motor phenotype. In contrast, transgenic mice overexpressing different forms of mutated 
human SOD1 develop a progressive motor neuron disease that closely resembles the 
pathology in human ALS. Mouse models with different mutations in the SOD1 gene vary in 
disease progression rate, not in the general phenotype however. A widely used SOD1 model 
for ALS harbors a G to A transition in position 93 (SODG93A). SODG93A mice develop 
hindlimb paralysis and die at 4-5 months of age (Gurney et al. 1994). The severe 
neuromuscular phenotype of these mice is accompanied by astrocyte and microglial 
activation, mitochondrial abnormalities, altered autophagy pathways and ER stress 
recapitulating many features of the human disease. Importantly, studies investigating 
different motor neuron populations, that are known to be affected in human ALS patients, 
revealed a significant loss of relevant populations also in different SOD1 models (Haenggeli 
and Kato 2002; Kashlan et al. 2015; Ferrucci et al. 2010; Nimchinsky et al. 1999). At the 
same time, the relatively resistant CN3/4 motor neurons are spared. In general, mutant SOD1 
mice are considered models for fALS. However, from the analysis of patient material it 
appears that the pathology and pattern of selective motor neuron vulnerability is similar in 
fALS and sALS (Shaw 1997; and reviewed in Peters et al. 2015), thus justifying the use of 
the available fALS models to understand sALS. We thus chose to use the SODG93A mouse 
model in studies I and II. 
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Figure 1.2. Timeline of SODG93A ALS mouse model. Approximate times for SODG93A overexpressing 
mice on a C57Bl/6J background. Lumbrical muscles of the hindlimbs show NMJ denervation at 84 days of 
age. Between 84 and 91 days, a decline in rotarod performance compared to littermate controls is evident. 
At the age of 112 days, around 50% of lumbar spinal (lSC) motor neurons with a diameter larger than 
20 µm are lost and the number of only partially innervated endplates in the tongue is increased. Mean 
survival for females is 153±1.7 days and males 147±1.6 days. Red numbers indicate timepoints 
investigated in studies I and II. Mice in study II were treated at the age of 80 days, immunohistochemistry 
was performed on symptomatic animals at 112 and 126 days. NMJ = neuromuscular junction; MN = motor 
neuron. (1Mancuso et al. 2012; 2Comley et al. 2016) 
1.6.2 SMA mouse models 
SMA is a monogenetic disease caused by the homozygous loss of functional SMN1. Mice 
only possess one gene encoding SMN (Smn) and its homozygous depletion is embryonically 
lethal (Schrank et al. 1997), whereas heterozygous depletion results in only a mild phenotypic 
change in the mice without reported effect on survival (Balabanian et al. 2007; Jablonka et al. 
2000). The embryonic lethality of complete SMN deletion can be rescued with the 
homozygous introduction of the human SMN2 gene (Smn-/-/SMN2+/+ (Monani et al. 2000)). 
These mice die at around postnatal day 6 and are considered a model of severe SMA (type I). 
Introduction of eight copies of SMN2 results in a complete rescue of the phenotype, which is 
in line with the disease-modifying role of SMN2 in human SMA. Another widely used mouse 
model of SMA has an additional transgene coding for the truncated version of the human 
SMN gene (Smn-/-/SMN2+/+/SMNΔ7+/+ (Le et al. 2005)) resulting in a slight extension of 
survival to 13-14 days. We chose this mouse model for study IV as it is still considered a 
model for severe SMA but allows more time for longitudinal investigation of disease 
mechanisms. Moreover, we have previously demonstrated the preservation of NMJs of 
CN3/4 motor neurons in this mouse model (Comley et al. 2016). 
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Figure 1.3. Timeline of ‘delta7’ mouse model of SMA. Motor neurons that innervate proximal and axial 
muscles (L1 and medial motor columns) are lost before motor neurons of the lateral motor columns that 
innervate limb muscles. Within the LAL, caudal and rostral bands show differential vulnerability. SMA 
mice display overt motor/behavioral symptoms from around seven days onwards: their righting reflex is 
impaired and SMA mice are significantly smaller than their healthy littermates. L = lumbar levels of the 
spinal cord; MN = motor neuron; sign. = statistically significant; TVA = transversus abdominus muscle; 
LAL = levator auris longis muscle; NF = neurofilament; EOM = extraocular muscle; 
NMJ = neuromuscular junction. Numbers in red indicate the time points investigated in study IV. (1Le et al. 
2005; 2Murray et al. 2008; 3Bäumer et al. 2009; 4Mentis et al. 2011; 5Comley et al. 2016) 
1.6.3 Cell culture models of ALS and SMA 
In vitro models of MNDs have been used extensively to study disease mechanisms and to test 
the efficiency of potential drugs. Primary motor neurons and other disease relevant cell types 
can be obtained from wild-type animals or transgenic animal models. The development of 
protocols for the derivation of relevant cell types from mouse and human embryonic stem 
cells has facilitated the use of in vitro models. Vulnerable spinal motor neurons have been 
successfully generated from stem cells by recapitulating events occurring during embryonic 
development (reviewed in Allodi and Hedlund 2014). Pluripotent stem cells are initially 
expanded and subsequently embryoid body (EB) formation is induced. EBs can form all three 
germ layers, neuroectoderm, mesoderm and endoderm. Spinal motor neurons are generated 
from progenitors through extrinsic signals that are present in a distinct gradient along the 
rostro- caudal and dorso- ventral body axes. More specifically, cervical spinal motor neurons 
are patterned by Sonic hedgehog (Shh), which is required for ventralization, and retinoic acid 
(RA), which mediates caudalization. Addition of Shh and RA to the cell culture medium 
induces the generation of several neuronal populations, including Hb9- and Islet1/2- positive 
motor neurons. With the development of induced pluripotent stem cells (iPSCs) from patient 
fibroblasts these in vitro models have gained even more relevance. 
iPSC-derived patient motor neurons and primary motor neurons from SMA mice 
have shorter neurites and/or axons (Rossoll et al. 2003; Corti et al. 2012). Moreover, SMA 
patient-derived motor neurons present a cell autonomous degeneration after six to eight 
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weeks in culture (Corti et al. 2012; Sareen et al. 2012). These characteristics can be easily 
assessed and used for the evaluation of disease modifiers such as IGF-2 in study II. 
Reactive astrocytes surround degenerating motor neurons in ALS patients as well as mouse 
models. When culturing motor neurons with mutant SOD1 astrocytes derived from transgenic 
mice, these astrocytes exert a toxic effect on motor neurons via soluble factors (Di Giorgio et 
al. 2007; Marchetto et al. 2008) (Figure 1.4). This is also true for astrocytes derived from 
familial and sporadic ALS patients (Meyer et al. 2014; Haidet-Phillips et al. 2011). 
Furthermore, astrocytes remove excess of the excitatory neurotransmitter glutamate via 
EAAT2 (GLT-1), which is down-regulated in ALS. Glutamate excitotoxicity has been 
implicated in ALS (Van Damme et al. 2007; Bruijn et al. 1997; Howland et al. 2002) and 
glutamate-overload of motor neurons in culture leads to increased cell death (Hedlund et al. 
2010). Both glutamate-overload of motor neuron cultures as well as co-culturing motor 
neurons with mutant astrocytes have therefore become widely used tools to model ALS-like 
toxicity in vitro. 
 
Figure 1.4. Mutant SOD1 astrocytes are toxic to motor neurons in vitro. (A) Schematic illustration of the 
co-culture system of astrocytes and human iPSC-derived motor neurons. Astrocytes are separated from 
motor neurons through a filter that allows for diffusion of soluble factors. Motor neurons are transfected 
with an Hb9-GFP construct to enable easy visualization of Hb9-positive cells. (B) Co-culture with mutant 
astrocytes significantly decreases motor neuron survival compared to co-culture with wild-type astrocytes. 
Student’s t-test, two-tailed, * = P<0.05. 
 
1.7 Disease mechanisms with a spotlight on motor neurons: a transcriptomics approach 
It is necessary to define alterations in pathways upstream and downstream of the disease-
causing gene to understand why some cell types are more vulnerable to degeneration than 
others. The use of transcriptomics presents an elegant way of dissecting such pathways by 
revealing gene expression changes in a tissue, cell population, or even a single cell. Several 
transcriptomics studies using different approaches have been conducted thus far and will be 
discussed here with emphasis on their experimental strategies. 
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1.7.1 Studies comparing disease versus health 
Early studies in SMA mouse models used whole spinal cord tissue to extract total RNA and 
compare gene expression and splicing to wild-type littermate controls at different disease 
stages (Murray et al. 2010; Bäumer et al. 2009; Zhang et al. 2008). However, cell type 
specific adaptation mechanisms cannot be distinguished with this approach as gene 
expression and splicing changes could be masked or equaled out by the numerous cell 
populations present in the spinal cord. To circumvent this problem, transcriptional profiling 
of enriched motor neurons isolated by laser capture microdissection (LCM) can be used. 
Among the common themes detected in such studies investigating ALS motor neurons and 
their respective healthy controls, were cell communication, cellular growth, energy 
metabolism, the untranslated protein response (UPR), and ER stress (Lobsiger et al. 2007; 
Ferraiuolo et al. 2007; Saxena et al. 2009; Bandyopadhyay et al. 2013). The activation of ER 
stress pathways was also revealed in a transcriptomics study using iPSC-derived motor 
neurons from SMA patients (Ng et al. 2015). Importantly, Ng et al. could demonstrate the 
moderate but yet positive effect of ER stress inhibitors in a mouse model of SMA. A draw-
back of these studies is however, that it is impossible to distinguish general adaptation 
mechanisms from detrimental responses that lead to the degeneration of selectively 
vulnerable cells. 
1.7.2 Studies comparing cell populations with differential vulnerability 
A different approach from comparing disease versus health is to compare vulnerable versus 
resistant cell populations. An early study by Hedlund et al. (2010) investigated differences in 
the transcriptomes of resistant CN3/4 and vulnerable hypoglossal and spinal motor neurons 
from LCM dissected cells of wild-type rats. Similarly, Brockington et al. (2013) compared 
LCM dissected CN3 motor neurons with spinal motor neurons from human post-mortem 
tissues from neurologically normal controls. Both studies found substantial intrinsic 
differences in these cell populations that could account for their differential susceptibility. A 
similar approach was undertaken by Kaplan et al. (2014) where ‘susceptibility and resistance 
candidates’ were identified by comparing two resistant motor neuron pools with vulnerable 
spinal motor neurons. One of their susceptibility candidates, MMP-9, had been shown earlier 
to be present in spinal motor neurons of ALS patients and its absence extended the life-span 
of SODG93A mice (Lim et al. 1996; Kiaei et al. 2007; Kaplan et al. 2014). Yet another study 
used a backlabeling technique to identify cells in the spinal cord that innervate different 
muscles consisting of either fast- or slow-twitch fibers, which are differentially affected in 
ALS (Saxena et al. 2009). The labeled motor neurons were isolated using LCM and subjected 
to microarray analysis. Upon identifying ER stress as an important disease mechanism, the 
investigators revealed that treatment of these mice with the ER stress-protective agent 
salubrinal ameliorated disease pathology and extended average survival significantly. 
Importantly, Kiskinis et al. (2014) could confirm ER stress as a major disease mechanism in 
motor neurons derived from human patient iPSCs with SOD1 mutations. Their analysis was 
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further extended to motor neurons derived from patients with sALS and C9ORF72 ALS 
patients. Among many differences between motor neuron transcriptomes, an overlap of gene 
expression changes associated with intracellular transport, oxidative stress and the UPR was 
found, indicating common mechanisms independent of the etiology of the disease. Taken 
together, these studies highlight the value of using differential susceptibility as a strategy to 
identify promising target mechanisms. When Kaplan and Saxena studied gene expression in 
the context of differential vulnerability, they were limited to the use of microarrays, which 
restricts the detection of genes to a given set of probes. RNA sequencing, however, opens up 
the possibility to reveal previously unknown transcripts and thus presents a valuable 
improvement to such strategies. 
In summary, transcriptional profiling of motor neurons can provide important insight into 
disease mechanisms. Including pre-symptomatic and symptomatic disease stages within a 
longitudinal analysis could aid in dissecting causative from consequential alterations in 
cellular biological processes. Furthermore, these findings demonstrate that identifying 
transcriptome alterations in vulnerable as well as resistant motor neuron populations can lead 
to de novo identification of detrimental and protective disease mechanisms and even potential 
drug targets. 
Given the variety of mechanisms implicated in ALS and the numerous functions of the 
disease-causing gene in SMA, it appears likely that the most promising treatment strategy 
will be a combination of factors rather than targeting only one aspect of motor neuron 
degeneration. Within this thesis work, we sought to develop a tool box and establish a 
comprehensive catalogue that can aid in understanding motor neuron susceptibility in ALS 
and SMA. We are exploring both, pathways of vulnerability and resistance, by first 
identifying them in mouse models of MND with the help of transcriptional profiling of 
neuronal populations with differential vulnerability. Confirmation on the protein level is 
initially achieved by immunohistochemistry on mouse tissues and subsequently in ALS 
patient tissues to evaluate their relevance for the human disease. With the same goal in mind, 
we use human iPSC-derived motor neurons to test the effect on survival of selected 
candidates. Lastly, promising candidates identified in the in vitro system are being evaluated 
in in vivo mouse models of MND (Figure 1.5). 
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Figure 1.5. Identification of pathways of degeneration and protection in motor neuron diseases. 
Workflow overview. 
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2 AIMS 
The overall aim of this thesis was to understand differential neuronal vulnerability in ALS 
and SMA and thereby elucidate underlying protective and detrimental adaptation 
mechanisms. We hypothesize that we can use oculomotor resistance as a tool to identify 
promising drug targets for the treatment of these so far incurable diseases. 
 
Paper I. To identify a protein signature for differentially affected motor neurons in ALS and 
investigate the conservation across species. 
 
Paper II. To demonstrate that oculomotor specific expression can be used to identify 
candidates that protect vulnerable motor neurons from degeneration in models of motor 
neuron disease. 
 
Paper III. To provide a robust and reliable protocol for spatial transcriptomic profiling that 
can be applied to scarce neuronal populations and human post-mortem tissues. 
 
Paper IV. To shed light on transcriptional adaptation mechanisms in differentially affected 
populations in SMA that could underlie their susceptibility to degeneration.  
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3 METHODOLOGICAL CONSIDERATIONS 
3.1 Mouse and human motor neuron disease models 
The translation of results achieved in mouse models of ALS and SMA to human clinical trials 
in general has been rather disappointing. While several mouse models recapitulate the human 
diseases fairly robustly, differences in phenotypes still prevail. SMA mouse models for 
example display severe defects in heart and liver tissues that are not typically observed in 
patients (apart from very severe cases, reviewed in Hamilton and Gillingwater 2013) that may 
alter disease progression significantly and appropriate read-outs have to be carefully 
considered. The previous limitation to mouse and rat models that are based on mutations in 
only one of many ALS genes (SOD1) has certainly contributed to the lack of clinical 
translation. The recently developed new mouse models based on several other ALS-causing 
genes such as FUS (Mitchell et al. 2013; Sharma et al. 2016), TARDBP (TDP-43, Walker et 
al. 2015; Spiller et al. 2016) and C9ORF72 (Liu et al. 2016) will benefit the translation of 
pre-clinical findings to human ALS. Another major problem is that due to its similarity to 
other neurological diseases at early stages, ALS is difficult to diagnose. Thus, patients 
recruited for clinical trials are typically at late stages of the disease when intervention might 
already be too late. Neurofilaments are the currently only reliable biomarkers for the 
diagnosis of ALS (Lu et al. 2012, 2015; Turner et al. 2013) and the further development of 
biomarkers will help overcome this problem. 
The strength of the methods applied in this thesis work lies in the combination of 
comprehensive studies in mouse models and the use of human ALS patient tissues as well as 
in vitro assays with human iPSC-derived motor neurons. We can thus reduce the number of 
animals used and at the same time maximize the chance of identifying mechanisms with 
relevance for the human disease. We use an animal in vivo system to identify candidates that 
could confer vulnerability and resistance (study IV). To evaluate if these candidates are 
persistently expressed in disease and could thus play a role in motor neuron susceptibility, we 
use immunohistochemistry on mouse tissues from MND models as shown in studies I and II. 
Subsequently, the relevance for the human disease is evaluated by performing 
immunohistochemistry on human control and patient tissues. Candidates that pass the initial 
screen need to be functionally tested. We decided to test the effect of IGF-2 on motor neuron 
survival in study II in two human iPSC- based in vitro models of ALS. The use of patient 
iPSC-derived motor neurons does not only allow us to evaluate the relevance for the human 
disease, it furthermore allows us to study disease modifiers in sporadic ALS. Finally, 
promising candidates are tested in mouse models of MNDs, as shown in study II, in order to 
evaluate effects on disease progression and survival in vivo. 
3.2 Advantages and limitations of laser capture microdissection coupled with RNA 
sequencing 
RNA sequencing is a powerful tool to understand the transcriptome of a cell or cell 
population and thus learn about biological processes and disease mechanisms. Paper III in 
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detail describes the LCM-seq method that we subsequently used in study IV. Here, I would 
like to elaborate on the advantages and limitations of using LCM-seq in the SMA 
transcriptomics study. 
 
Figure 3.1. Overview LCM-seq workflow. Brain and spinal cord tissues are rapidly dissected and snap 
frozen. Coronal sections are prepared in a cryostat at -20°C (at a thickness which corresponds 
approximately to the diameter of the cells of interest) and mounted onto pre-cooled LCM membrane slides. 
Sections are stained with a quick histological staining immediately before LCM to visualize cell somas. 
Individual cells are cut with a laser and collected in dry PCR tubes. Cells are lysed in a mild hypotonic 
lysis buffer and cDNA libraries are prepared directly in the same tube using the Smart-seq2 protocol. 
Quality of cDNA libraries is evaluated with a Bioanalyzer (Agilent) before sequencing library preparation. 
Amount of cDNA in FU = fluorescent units; fragment size in bp = base pairs. LCM = laser capture 
microdissection. 
3.2.1 Laser capture microdissection for the isolation of neuronal populations 
For study IV, we wanted to compare the transcriptomes of six different neuronal populations, 
namely motor neurons of the spinal cord, motor neurons of the oculomotor and trochlear 
nuclei, the facial nucleus, the hypoglossal nucleus and the dorsal motor nucleus of the vagus 
nerve, as well as neurons of the red nucleus. There are no genetic markers that reliably 
distinguish all our populations of interest, making genetic labeling and the widely-used 
fluorescence-activated cell sorting (FACS) an unsuitable method for cell isolation in our 
study. Furthermore, brain and spinal cord tissues from postnatal mice do not allow for easy 
dissociation that is necessary for FACS, due to increased myelination and long cellular 
processes. Therefore, our method of choice was laser capture microdissection (LCM). For 
LCM, tissue was snap frozen immediately after dissection, followed by sectioning in the 
cryostat in order to prevent RNA degradation. Due to their large soma size and distinct 
location in the brainstem and spinal cord, we can easily identify motor neurons and neurons 
of the red nucleus using a histological staining. This staining is commercially available and 
optimized for RNA analysis after LCM (histogene, Arcturus). For laser dissection, each cell 
is being outlined individually, closely to the margins of the cell, in order to keep the inclusion 
of contaminating cells to a minimum (Figure 3.2). 
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Figure 3.2. LCM for isolation of highly enriched neuronal populations. (A) Whole spinal cord 
section stained with histological staining (histogene) to visualize cell somas; rectangle indicates 
area that is shown in (B). Inset: cutting outlines (red) are drawn closely around the cell in order to 
minimize the inclusion of surrounding cells. Only cells with clear nucleus and nucleolus are 
selected in order to avoid capturing cells that might lie underneath the motor neuron. (C) Tissue 
after laser dissection. Scale bar in A = 200 µm, in C (applicable to B and C) = 100 µm. 
One significant limitation of using LCM in our study is that we are restricted to investigating 
RNA species in the cell soma. Motor neurons possess long axonal processes and mRNAs are 
highly abundant all the way to the presynaptic terminals of these cells. Given the role of SMN 
in axonal RNA regulation, it would be interesting to include these RNAs in our analysis to 
gain insight into potential SMA-induced alterations in their regulation. Transcriptional 
profiling of LCM dissected NMJs has been performed previously (Ketterer et al. 2010), it 
remains challenging however, to identify motor neuron-derived transcripts in this setup as a 
substantial proportion of the dissected material derives from muscle tissue. In vitro 
microfluidic systems present an elegant way to circumvent this problem (Southam et al. 
2013; Saal et al. 2014; Briese et al. 2015). Here, muscle cells and motor neurons can be co-
cultured in separate compartments that are connected by micro-channels and thus only allow 
axons to cross. Due to the small amount of material isolated from crossing axons in the 
micro-channels, technical challenges remain also here. 
3.2.2 Smart-seq2 for sequencing library preparation from laser capture microdissected 
cells 
For optimal RNA sequencing results, large amounts of high quality input material are 
required. Recently, sequencing of single cells has become a widely-used method to explore 
the heterogeneity of cell types and identify new cell types and thus protocols for extremely 
low input material have been developed. We chose to use a single cell protocol for RNA 
sequencing library preparation to keep the number of cells collected comparably low. 
Previous studies applying LCM coupled with RNA sequencing use 200 – 4000 cells and 
sometimes required pooling of cells from several animals (Kadkhodaei et al. 2013; Zhang et 
al. 2013; Bandyopadhyay et al. 2013; Murray et al. 2015). Low input material, however, 
comes at the cost of increased technical variation and bias due to the necessity of 
amplification of the material. In particular, low abundant transcripts might be lost during 
exponential PCR amplification cycles. Nevertheless, using a protocol for low input material 
means less time spent for collection per sample and thus more samples collected in the end. 
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In this way, we reduced technical variations by increasing the number of biological replicates, 
aiming for a sample size of n = 5 animals per group. Our bioinformatic analysis shows that 
we can detect several differentially expressed genes over a range of expression levels, also at 
small fold changes, highlighting the sensitivity of the protocol. 
We chose to collect approximately 150 cells per cell population in order to represent the 
whole population rather than a subset of very heterogeneous motor neurons. We do 
acknowledge, however, that by analyzing bulk samples, we might lose biologically relevant 
information considering the vulnerability gradient within certain motor neuron pools. In 
SMA, spinal motor neurons of the medial motor column degenerate before lateral cells are 
lost. Within the levator auris longus (LAL) muscle, that receives input from the facial motor 
nucleus, the caudal band shows denervation whereas the rostral band appears to be resistant. 
However, employing single cell sequencing for our already complex study design (six 
differentially affected cell populations x three time points x two genotypes) seemed 
unfeasible. Nevertheless, we have gained important insights into SMA disease mechanisms 
that we can further interrogate on the single cell level in selected populations in future 
studies. 
3.2.3 Full-length RNA sequencing: splicing analysis remains a challenge 
Smart-seq2 uses oligo-d(T) primers and thus selects for poly(A)+ transcripts but at the same 
time shows improved read coverage of the whole transcript length (gene body coverage) 
(Picelli et al. 2013). Sufficient gene body coverage is crucial for splicing analysis, which is 
particularly pertinent when studying SMA due to the function of the SMN protein in the 
assembly of the spliceosome. 
We found a rather strong 3’ bias of read coverage in our samples and initial splicing 
analysis led to the detection of only few significant splicing event changes, limited to the 3’ 
end of the transcripts (Figure 3.3). Increased sequencing depth slightly improved the 
detection of splicing events over the whole transcript body when we performed analysis on 
pooled samples, but our results lacked biological significance when subsequently examining 
individual replicates. We therefore concluded that we cannot perform robust splicing analysis 
over the whole transcriptome for this study. 
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Figure 3.3. Splicing event detection improves with read depth but reveals differences in coverage 
along the transcript length. (A) Splicing analysis performed on individual samples revealed a 
constant decrease of detected splicing events from the 3’ to the 5’ end (exemplified for spinal cord 
samples). (B) Splicing analysis on pooled samples seemed to lead to a milder decrease in events 
detected towards the 5’ end of the transcripts. (C) More splicing events were detected with 
increased sequencing depth. Colored numbers in A and B indicate the read depth of selected 
samples (million mapped reads). 
The poor gene body coverage could be of many origins, the most obvious being RNA 
degradation that might occur during the several tissue processing steps. Preliminary analysis 
indicates that the RNA quality in our samples is compromised during the staining procedure 
for LCM. We prepared cDNA libraries from (1) stained tissue chunks and (2) tissue sections 
that had undergone the washing and dehydration steps (with ddH2O and ethanol) while 
omitting the actual staining solution and compared them to (3) cDNA libraries obtained from 
unstained tissue chunks (air dried only) (Figure 3.4). cDNA profiles as measured with a 
Bioanalyzer (Agilent) visualize the fragment size distribution of a library and are good 
indicators of input RNA quality. cDNA libraries from tissue sections that were air dried only 
were of the highest quality, whereas unstained but H2O- and ethanol- treated chunks resulted 
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in significantly better quality than samples stained with histogene staining solution. 
Sequencing data are necessary to better evaluate the gene body coverage obtained from the 
different tissue processing conditions. Nevertheless, we anticipate that by improving the 
staining procedure RNA degradation can be substantially decreased and thus gene body 
coverage increased. 
 
Figure 3.4. RNA quality is likely compromised during histogene staining procedure. (A) Examples of 
stained and unstained tissue sections before and after laser dissection of tissue chunks. Adjacent sections 
were used in order to ensure the inclusion of similar tissues. Scale bar in top right panel = 100 µm. (B) 
Examples of cDNA profiles that illustrate the difference between air dried (blue), unstained but H2O- and 
ethanol- treated (red) and histogene stained (turquoise) tissue chunks. Fragment size is shown as migration 
time in seconds (s). The peak at 60 s corresponds to a fragment size of approximately 300 base pairs (bp) in 
all samples. Main upper peaks correspond to: ~ 900 bp (stained; turqouise), ~ 1500 bp (H2O/ethanol; red) 
and ~ 2000 bp (air dried; blue). (C) Input RNA quality was estimated by calculating the ratio of the area 
under the curve between 600 – 3000 bp (range of mammalian RNA (Lewin 2008)) and 100 – 600 bp, and 
shows that RNA from tissue chunks that were air-dried only was best preserved, while the small ratio for 
histogene stained samples suggest RNA degradation. Boxplots with individual values and whiskers 
representing minimum and maximum. One-way ANOVA was performed with GraphPad Prism6, F (2, 22) 
= 21.90, Tukey’s multiple comparison test; * = P<0.05, ** = P<0.01, **** = P<0.0001. 
Another possible source of incomplete gene body coverage is inefficient reverse transcription 
(RT) of RNA species. RT enzymes have to overcome secondary structures in the RNA 
making RT along the full transcript length a challenge. Furthermore, performing this reaction 
directly in cell lysates as is the case for the Smart-seq2 protocol might have the presence of 
inhibitory factors as a consequence. Indeed, in paper III, we observed a slightly better gene 
body coverage for samples that had undergone RNA extraction before cDNA preparation 
indicative of more efficient RT in purified samples (Figure 3.5). For the development of the 
Smart-seq2 protocol several RT enzymes, buffer compositions and reaction conditions have 
been compared. In the meanwhile, new, improved RT kits are available from several 
providers and it will be worthwhile to test the latest protocols on LCM dissected cells. 
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Figure 3.5. Compromised 
gene body coverage in LCM 
dissected motor neurons 
compared to live single motor 
neurons. Exemplified for 
transcripts that are shorter than 
3 kilo bases. Samples that had 
undergone RNA extraction 
prior to cDNA preparation 
(Extract) displayed slightly 
improved coverage compared 
to samples where reverse 
transcription was performed in 
cell lysates. Numbers on the 
vertical axis indicate the 
number of cells collected. MN 
= motor neuron. 
In summary, we are optimistic that by adjusting different steps in the protocol we will 
ultimately be able to achieve sufficient gene body coverage to perform also robust splicing 
analysis using this method. Nevertheless, we demonstrate here that we can obtain important 
insight into gene expression level changes in closely related neuronal populations using 
LCM-seq as discussed in paper III and IV. While we cannot entirely exclude the possibility 
that some transcripts detected originate from contaminating glial cells, the expression of 
multiple genes identified in study IV could be confirmed in motor neurons using the 
extensive in situ database provided by the Allen Institute for Brain Research (Lein et al. 
2007). Further investigation via in situ hybridization and immunohistochemistry on healthy 
and SMA tissues will refine the candidate list for functional studies in in vitro and in vivo 
models of SMA as demonstrated in paper I and II. 
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4 RESULTS AND DISCUSSION 
We are investigating cell intrinsic mechanisms that render some motor neurons, including 
oculomotor (CN3) and spinal motor neurons, resistant or vulnerable to degeneration in ALS 
and SMA. We hypothesize that we can use this differential vulnerability as a tool to identify 
drug targets for the treatment of human motor neuron diseases. In this thesis, we could 
demonstrate a distinct protein signature of different motor neuron populations that is 
relatively conserved in mouse and man. Moreover, we validated oculomotor resistance as a 
tool to identify candidates that can protect vulnerable motor neurons in vitro and in vivo. We 
have furthermore developed a protocol for robust RNA sequencing of LCM dissected cells 
(LCM-seq), that can aid in further elucidating transcriptional adaptations in closely related 
neuronal populations. We applied LCM-seq to explore disease mechanisms in a mouse model 
of SMA and were able to dissect shared and cell type specific transcriptional changes that 
provide insight into differential vulnerability in this motor neuron disease. In this section, I 
will describe the most important findings of each study in more detail. 
 
4.1 Paper I. Motor neurons with differential vulnerability to degeneration 
show distinct protein signatures in health and ALS 
Through a previous transcriptome analysis in the normal healthy rat, we could identify 
several transcripts that are preferential to resistant oculomotor neurons or vulnerable spinal 
and hypoglossal motor neurons and could thus underlie their differential susceptibility to 
degeneration in MNDs (Hedlund et al. 2010). Based on their function, we have chosen 
promising candidates (Table 4.1) that we here further investigated in the SODG93A mouse 
model of ALS and in human post-mortem patient tissues. In this study, we used 
immunohistochemistry to examine the expression of our candidates on the protein level and 
how they change in disease.  
Table 4.1. Candidate genes selected for cross species analysis in health and ALS based on differential 
mRNA expression.  
 
(references can be found in the corresponding section of Paper I) 
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4.1.1 Proteins with implications for motor neuron vulnerability and resistance are 
regulated in ALS 
We have shown that several proteins with implications for motor neuron resistance, including 
GABAA receptor α1, guanylate cyclase soluble subunit alpha-3 and parvalbumin, were 
persistently expressed in oculomotor neurons in control (Table 4.2). Proteins with 
implications for vulnerability like dynein, peripherin, and GABAA receptor α2, which play 
roles in retrograde transport and excitability, and could place motor neurons at an increased 
risk, were found at higher levels in vulnerable motor neurons. 
Table 4.2. Summary of candidate protein analysis across species in health and ALS.  
 
 
With the exception of Gabra2, all candidates investigated here were modulated when 
challenged with a disease-causing mutation underlining their importance for normal motor 
neuron function. As their regulation could either be beneficial or detrimental, it could be 
causal or an effect of the disease, functional studies in in vitro and in vivo models of ALS are 
crucial in order to evaluate the nature of their regulation. Nevertheless, these proteins 
constitute important pieces of a so far unsolved puzzle that can help us to understand the 
basis of differential neuronal susceptibility in ALS. 
4.1.2 Conservation of the protein signature in mouse and man 
Importantly, the expression patterns of our candidates were highly similar in mouse and 
human supporting their relevance also for the human disease (Table 4.2). The relative 
conservation of signals across species infers that SODG93A ALS mice could be used to predict 
mechanisms of neuronal vulnerability in man.  
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4.2 Paper II. Differential neuronal vulnerability identifies IGF-2 as a 
protective factor in ALS 
In paper II, we have further investigated the potentially protective role of the CN3/4 restricted 
neurotrophic factor insulin-like growth factor 2 (IGF-2) as IGFs are known motor neuron 
survival factors (Silva et al. 2009; Eustache et al. 1994). Like in paper I, we initially 
examined the presence of IGF-2 protein with immunohistochemistry in symptomatic ALS 
mice and in human patients. To functionally evaluate its effect in ALS, we tested if IGF-2 
could protect vulnerable spinal motor neurons in in vitro models of ALS-like toxicity and 
subsequently performed in vivo experiments in SODG93A ALS mice. 
4.2.1 IGF-2 is preferential to oculomotor neurons in symptomatic ALS mice and in end-
stage ALS patient tissues 
In order to evaluate if IGF-2 could play a role in oculomotor resistance, we first investigated 
its protein expression in symptomatic ALS mice and human end-stage ALS tissues and found 
significantly higher levels in resistant oculomotor compared to vulnerable hypoglossal and 
spinal motor neurons (Figure 4.1). Furthermore, IGF-1 receptor, which mediates survival 
pathways upon IGF binding, was also preferentially expressed in oculomotor neurons as well 
as on extraocular muscle endplates. This indicates that IGF-2 could have a protective role in 
the extraocular system that is absent in vulnerable spinal motor units. 
 
Figure 4.1. IGF-2 protein is persistently expressed in resistant oculomotor neurons in ALS end-stage 
tissues. Immunohistochemistry was used to visualize IGF-2 protein expression in oculomotor (CNIII, A 
and E), hypoglossal (CNXII, B and F) and spinal (SC, C and G) motor neurons. In line with our results 
from the mouse tissue analysis, IGF-2 protein levels were highest in resistant oculomotor neurons in human 
control (A-D) and ALS patients (E-H). (D, H) Quantifications of staining intensity. One-way ANOVA with 
Bonferroni multiple comparison correction. *** = P<0.001, * = P<0.05. Scale bar in G applicable to A-C 
and E-G = 30 µm. 
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4.2.2 IGF-2 can protect vulnerable human motor neurons in vitro 
To functionally support our hypothesis that oculomotor restricted factors could play a role in 
their resistance, we initially used two in vitro models of ALS-like toxicity to perform gain-of-
function studies: glutamate- and mutant astrocyte- induced toxicity. Using iPSC-derived 
motor neurons from human ALS patients and controls, we showed that the addition of IGF-2 
to the cell culture medium after initiation of toxicity significantly improved the survival of 
these vulnerable motor neurons in both assays (Figure 4.2). We furthermore demonstrated 
that the protective effect of IGF-2 is likely elicited by the activation of the PI3/Akt survival 
pathway as evidenced by the increased phosphorylation of Akt and GSK3β. The increased 
phosphorylation and thus inhibition of GSK3β is in line with a previous study that identified 
the GSK inhibitor kenpaullon as a survival factor for ALS patient- derived motor neurons 
(Yang et al. 2013). 
 
 
Figure 4.2. IGF-2 protects human 
iPSC-derived motor neurons from 
ALS-like toxicity. Shown here are the 
results from motor neuron cultures that 
were exposed to mutant astrocytes (A) 
without and (B) with the addition of 
IGF-2 to the cell culture medium. (C) 
Motor neuron survival was significantly 
increased by the addition of IGF-2. 
Values represent mean±SD from 5 
independent experiments performed in 
triplicate. One-way ANOVA with post-
hoc comparison, ** = P<0.01. 
 
4.2.3 IGF-2 ameliorates disease in a mouse model of ALS 
Due to the positive results in our in vitro experiments, we further asked if viral delivery of 
IGF-2 to motor neurons could protect them in the SODG93A mouse model of ALS. We used 
an adeno-associated virus vector (AAV9) expressing IGF-2 that was injected bilaterally into 
the hindlimb quadriceps and thoracic muscles at an early symptomatic stage. From the 
muscle, AAV9 is transported retrogradely to the soma of motor neurons to drive transgene 
expression. Compared to AAV9::null injected controls, the IGF-2 treated mice lived longer 
(on average 14 days) and had improved motor function as evaluated by rotarod. In treated 
mice that were sacrificed when the control reached end-stage, we found more motor neurons 
in the lumbar spinal cord and a higher axon density in the respective ventral roots. As 
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assessed by GAP-43 expression, a growth and regeneration marker (Verhaagen et al. 1988), 
we conclude that induction of a regenerative response in motor neurons of symptomatic mice 
could contribute to the amelioration of the disease phenotype (Figure 4.3). 
 
Figure 4.3. IGF-2 extends the survival of SODG93A mice by preserving motor neurons and inducing 
nerve regeneration. (A) Mice were injected at the age of 80 days with AAV9::IGF-2 or AAV9::null into 
hindlimb quadriceps and thoracic muscles from where viral particles are retrogradely transported to the 
spinal cord. (B) Survival of IGF-2 treated mice was significantly extended by 14 days (Kaplan- Meier 
survival curve, χ2 =5.3, P=0.02). (C) Motor neuron loss in IGF-2 treated mice was ameliorated. (D) GAP-
43 staining of lumbrical NMJs indicated a regenerative response in IGF-2 treated mice. Control = 
AAV9::null injected mice, wt = wild-type untreated; One-way ANOVA with post-hoc comparison, ** = 
P<0.01. Scale bar in E, applicable to D and E = 40 µm. 
 
Within the scope of this thesis, I would like to emphasize study II as a functional proof of 
concept for our approach. Here, we functionally demonstrated the protective effect of the 
oculomotor-restricted factor IGF-2 in vulnerable spinal motor neurons. We acknowledge, 
however, that loss-of-function studies are necessary to determine if IGF-2 plays a role in 
conferring resistance to oculomotor neurons. This could be tested by abolishing IGF-2 
signaling in oculomotor neurons via stereotactic injections of shRNA into the oculomotor 
nucleus to block the survival-mediating IGF1R signaling. A complimentary approach would 
be the use of an in vitro system that assesses the survival of mESC- or iPSC-derived 
oculomotor neurons. Both strategies would however make it impossible to assign the 
resulting effects to IGF-2 specifically, as IGF-1 has a higher affinity for this receptor. 
Nevertheless, we would gain further insight into the role of IGFs in oculomotor resistance. 
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4.3 Paper III. Laser capture microscopy coupled with Smart-seq2 for precise 
spatial transcriptomic profiling 
RNA sequencing has increasingly become a method of choice for exploring gene expression 
in biological organisms including man and mouse. It presents a powerful tool to understand 
cellular diversity and dissect normal biological processes and disease mechanisms. Often 
target tissues are scarce, such as human patient tissues or small cellular populations, and thus 
protocols for limited amounts of input material are necessary. Single cell RNA sequencing 
has become more and more feasible and is being successfully applied to live cells. Where 
tissues do not allow for easy dissociation or unique genetic markers are lacking for isolation 
of target cells (for example by FACS) other means of cell isolation are needed. Laser capture 
microscopy (LCM) can be used to dissect individual cells while preserving their positional 
information and it can be combined with antibody stainings to identify cell types of interest. 
Previously, the number of cells required to perform RNA sequencing after LCM dissection 
has been rather large with hundreds if not thousands of cells. Here, we have developed LCM-
seq that couples LCM with Smart-seq2, a protocol for single cell RNA sequencing, for robust 
and efficient transcriptomic profiling of neuronal populations from snap frozen mouse and 
human tissues. 
4.3.1 LCM-seq is reproducible and sensitive down to single cells 
We initially collected 120 mouse spinal motor neurons and in order to find the minimum 
amount of input material needed, subsequently scaled down the number to single LCM 
dissected cells. The Smart-seq2 protocol employs reverse transcription of RNA directly from 
lysed cells and thereby circumvents the extraction of RNA and thus loss of material. In this 
way, while reducing cost and time, we were able to successfully prepare cDNA and 
sequencing libraries from only few cells with high success rates: 62% of the single mouse 
motor neurons, 82% of two cell samples and 100% of the samples collected with five or more 
cells passed our quality control and were used for further analysis. We could demonstrate a 
high reproducibility in gene detection for bulk samples, whereas the more variable expression 
profiles of fewer cells on the one hand indicates higher technical variation but can partly be 
explained by their biological variability (Figure 4.4). Encouragingly, we detected a 
comparable number of genes in single LCM dissected cells and live motor neurons derived 
from mouse embryonic stem cells (mESCs).  
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Figure 4.4. LCM-seq is robust and sensitive down to single cells. (A) Spearman correlation (including all 
genes expressed ≥1RPKM in at least one sample) and (B) principal component (PC) analysis of top 500 
variable genes revealed highly related transcriptomes of samples with more than 10 cells. Lower 
correlation and larger spread of samples with 5, 2 and 1 cell reflects technical noise as well as biological 
heterogeneity of motor neurons. 
As spinal motor neurons have a large soma and are metabolically active cells, they likely 
contain comparably large amounts of RNA. We therefore tested if LCM-seq is sensitive 
enough for single cell sequencing of smaller cells with presumably less RNA. The success 
rate for small neurons decreased substantially (16% of single cells and 33% of 5-cell samples 
passed the quality control). Thus, for cells of smaller size/RNA content it is important to 
increase the number of samples collected initially in order to obtain a sufficient sample size 
for analysis. Adjusting the staining protocol prior to LCM as discussed in the chapter 
‘Methodological considerations’ may prevent RNA degradation and improve the success 
rate. Yet another strategy could be to increase the number of amplification cycles during 
cDNA preparation. However, care must be taken as non-linear PCR amplification leads to the 
enrichment of highly abundant transcripts with the risk of losing low-abundance species. 
Nevertheless, in our study of small neurons, we could still detect an average of approximately 
5,000 genes in one-cell samples and 7,000 genes in five-cell samples, making LCM-seq 
applicable to a variety of cell types. 
4.3.2 LCM-seq can be used to distinguish closely related cell populations 
We next tested if our method is sensitive enough to distinguish closely related cell 
populations, namely motor neurons isolated from different levels of the spinal cord. Using 
principal component analysis with the top 500 variable genes we found a clear separation of 
the two groups along the first component accounting for 51% of the variability in all samples. 
Among the top differentially expressed genes were numerous Hox transcription factors that 
confer positional identity during embryonic development. Besides serving as a positive 
control for distinguishing neurons derived from different positions along the anterior-
posterior body axis, the persistent postnatal expression of Hox genes confirmed previous 
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results in the rat (Hedlund et al. 2010). In total, we identified 899 genes with differential 
expression in motor neurons of the cervical and lumbar spinal cord, demonstrating that LCM-
seq can be used to dissect transcriptional differences in closely related cell populations. 
 
Figure 4.5. LCM-seq reveals distinct transcriptomes of closely related cell types that locate to different 
positions along the anterior- posterior body axis. (A) Motor neurons of the cervical (cSC) and lumbar 
(lSC) spinal cord separated clearly on the first component (PC1) in principal component analysis of the top 
500 variable genes. (B) Among the top 20 differentially expressed were several Hox transcription factors 
that confer positional identity during embryonic development (shown as mean±SEM). 
4.3.3 LCM-seq reveals transcriptomes of human neurons 
Importantly, we could demonstrate that LCM-seq can be applied to human tissues that are 
partially degraded due to long processing times. We obtained robust sequencing data from 
midbrain dopamine neurons and spinal motor neurons with more than 10,000 genes 
expressed (≥1 RPKM) on average, in samples that contained less than 200 cells. 
Reassuringly, we found 4,903 differentially expressed genes between the two cell types.  
Motor neurons can be easily identified by their large soma size and location and 
human dopamine neurons are characterized by their neuromelanin coat and thus a quick 
histological staining is sufficient prior to LCM. In order to test if our method could also be 
applied when identification of cells requires antibody staining with longer incubation times, 
we isolated dopamine neurons after staining with an anti-tyrosine hydroxylase antibody. 
Although the number of genes detected decreased compared to the histological staining (912 
genes less, ≥ 0.1 RPKM), we could still detect 11,420 genes expressed at ≥ 1 RPKM, 
including dopamine neuron markers. Thus, LCM-seq can be applied to numerous cell 
populations that can be identified by antibody stainings. (Figure 4.6) 
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Figure 4.6. LCM-seq is applicable to partly degraded human post-mortem tissues and can be combined 
with antibody stainings. (A) On average, more than 10,000 genes (≥ 1 RPKM) were detected in spinal 
motor neurons (MN) and dopamine neurons of the substantia nigra pars compacta (SNc) and ventral 
tegmental area (VTA) (histological staining). (B) Clustering of midbrain dopamine neurons (mDA) and 
spinal MN based on the top 500 variable genes showed a clear separation of the two cell types. (C) A larger 
number of genes (≥ 0.1 RPKM cutoff) was detected when applying histological staining compared to 
antibody staining (Student’s t-test, P=0.03). Values shown as mean±SEM. 
Finally, we tested if LCM-seq can be successfully applied to single human motor neurons. 
Whereas mouse brains and spinal cord tissues were dissected in a few minutes (less than three 
and 15 minutes, respectively), processing times for human tissues used in this study were 
between three and ten hours likely resulting in increased RNA degradation. Nevertheless, we 
found an average of 7,655 genes expressed in these cells and could detect motor neuron 
markers like MNX1 (Hb9), ISLET1/2 and CHAT indicating that this method can be applied 
for single cell analysis of human tissues. 
Taken together, we have developed a robust and reliable protocol for transcriptomic profiling 
of LCM dissected cells that can be applied to scarce neuronal populations and human post-
mortem tissues. Our approach could thus be broadly used for studying general biological 
processes as well as human disease mechanisms. 
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4.4 Paper IV. Resistant and vulnerable motor neurons display distinct 
transcriptional regulation in spinal muscular atrophy 
Spinal muscular atrophy (SMA) affects somatic motor neurons of the lower brainstem and 
spinal cord due to a deficiency in the broadly expressed survival of motor neuron (SMN) 
protein while oculomotor and trochlear (CN3/4) motor neurons are spared. In this study, we 
aimed for a comprehensive catalogue of transcriptional changes throughout disease 
progression in several differentially affected neuronal populations in order to better 
understand general disease mechanisms as well as neuronal susceptibility. We used LCM-seq 
to obtain gene expression profiles of vulnerable motor neurons (spinal cord (SC) and facial 
nucleus (CN7)) and of relatively resistant populations (oculomotor and trochlear (CN3/4) and 
hypoglossal (CN12) nuclei). We furthermore collected transcriptome data from visceral 
motor neurons of the vagus nerve (CN10) and neurons of the red nucleus (RN) that served as 
controls. (Figure 4.7) 
 
Figure 4.7. Cell populations with differential vulnerability have distinct locations in the brainstem and 
spinal cord. Lumbar spinal motor neurons (SC) are affected early in disease, whereas facial motor neurons 
(CN7) display pathology later (Murray et al. 2010). Hypoglossal (CN12) and oculomotor and trochlear 
(CN3/4) motor neurons are relatively resistant (Comley et al. 2016). Motor neurons of the vagus nerve 
(CN10) lie in close proximity to CN12 and serve as positional and importantly as a visceral motor neuron 
control that are unaffected in MNDs. Neurons of the red nucleus (RN) are located adjacent to CN3/4 motor 
neurons and share a developmental origin with these. They are unaffected in SMA and serve as a non-
motor neuron control. Asterisks (*) highlight vulnerable populations. 
4.4.1 Oculomotor neurons display a transcriptional profile that is distinct from other 
somatic motor neurons 
Our initial analysis of the entire gene expression profile showed that the transcriptome of 
CN3/4 motor neurons is distinct from other somatic motor neurons confirming previous 
findings in mouse, rat and human (Kaplan et al. 2014; Hedlund et al. 2010; Brockington et al. 
2013). Yet, CN3/4 motor neurons appear to be more closely related to somatic motor neurons 
than to visceral CN10 motor neurons which has not been disclosed in previous studies due to 
the lack of visceral motor neuron controls. (Figure 4.8) 
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Figure 4.8. Distinct transcriptional profile of resistant CN3/4 motor neurons. (A) Spearman correlation 
showed that transcriptomes of somatic motor neurons of SC, CN7 and CN12 are highly correlated, whereas 
CN3/4 motor neurons clustered closer with RN neurons. (B) Principal component analysis of all genes 
expressed revealed that CN3/4 motor neurons are transcriptionally more similar to somatic motor neurons 
than visceral CN10 motor neurons. p = postnatal day. 
4.4.2 Shared gene expression changes in somatic motor neurons imply DNA damage as a 
disease mechanism in SMA 
Compared to our unaffected controls, RN and CN10, which both displayed regulation of 81 
genes, we found substantially higher numbers of disease-induced differentially expressed 
genes in vulnerable as well as resistant somatic motor neurons (Figure 4.9). Comparable 
SMN mRNA levels in all groups investigated suggest that there is a qualitative difference in 
the need for SMN protein between cell types rather than a quantitative. We do acknowledge 
however, that the difference might lie in the efficiency to include exon 7 of the SMN2 gene 
and thus produce full length transcripts and protein, which we cannot address with our study 
design as discussed earlier (section ‘Methodological considerations’). Motor neurons appear 
to have a low intrinsic efficiency to include exon 7 compared to other cell populations of the 
spinal cord. The primers specific for full length SMN mRNA derived from SMN2 used in the 
study by Ruggiu et al. (2012) can be applied to investigate the efficiency of exon 7 inclusion 
in different neuronal populations including somatic motor neurons with differential 
vulnerability. Future investigations will thus shed light on this question. 
While the overlap of differentially expressed genes was relatively low, suggesting cell 
type specific adaptation mechanisms, we could still identify common themes that were shared 
between all somatic motor neurons (Figure 4.9B). Most prominent was the activation of cell 
cycle, apoptosis and p53 pathway-related genes, including Cdkn1a (p21), Gtse1, Plk2, Fas, 
Pmaip1 and Ptprv that were differentially expressed in all somatic motor neurons. We also 
found these commonly regulated genes to be the strongest drivers of the genotype component 
in the principal component analysis of our most vulnerable (SC) and most resistant (CN3/4) 
groups. These findings are in line with several other SMA transcriptomics studies (Bäumer et 
al. 2009; Zhang et al. 2013; Maeda et al. 2014; Murray et al. 2015; Ng et al. 2015; Doktor et 
A
0.8 0.9
SMA
control
-1.0 - 0.5 0.0  0.5 1.0
1.4
1.2
- 0.4
1.0
0.8
0.4
0.6
0.2
- 0.2
0.0
weighted mean log2 PC1 (7.49%)
we
igh
te
d 
m
ea
n 
log
2 
PC
2 
(5
.4
7%
)
CN10 p2
CN10 p5
CN10 p10
CN12 p2
CN12 p5
CN12 p10
CN3/4 p2
CN3/4 p5
CN3/4 p10
CN7 p2
CN7 p5
CN7 p10
RN p2
RN p5
RN p10
SC p2
SC p5
SC p10
SMA
control
CN10 p2
CN10 p5
CN10 p10
CN12 p2
CN12 p5
CN12 p10
CN3/4 p2
CN3/4 p5
CN3/4 p10
CN7 p2
CN7 p5
CN7 p10
RN p2
RN p5
RN p10
SC p2
SC p5
SC p10
B
  37 
al. 2016; Staropoli et al. 2015). P53 is a master regulator in response to several cellular 
stressors such as oxidative stress or DNA damage that can potentially lead to apoptosis. Even 
though the evidence for DNA damage in SMA is as yet limited, SMN could protect against 
transcriptional DNA damage through resolving R-loop formation (Zhao et al. 2015). FUS and 
TDP-43, which when mutated cause ALS, are involved in RNA regulation. As evidenced by 
increased DNA damage upon their depletion, FUS and TDP-43 contribute to the prevention 
or repair of transcription-associated DNA damage (Hill et al. 2016) and it appears that loss of 
SMN could have a similar result. Interestingly, a recent study demonstrated the presence of 
increased pH2AX, a marker for DNA repair complexes, in relatively resistant motor neurons 
of wild-type mice suggesting a higher intrinsic capacity for DNA damage repair. In resistant 
populations of SMA mice however, the marker was detectable at comparable levels to 
vulnerable motor neurons (Murray et al. 2015). Our analysis suggests that alternative 
protective mechanisms, potentially further downstream, could be at play. Within the p53 
pathway, we found Aldh4a1, that can protect cells from oxidative stress (Yoon et al. 2004), 
and Pak4, a neuroprotective CDKN1A activated caspase inhibitor (Gnesutta et al. 2001; 
Gnesutta and Minden 2003; Won et al. 2016) to be up-regulated in CN3/4. Altogether, these 
findings suggest DNA damage as a disease mechanism in SMA and it will be interesting to 
disclose to what extent resistant and vulnerable populations are affected. 
Immunohistochemistry can be used to detect DNA damage markers like γH2AX (Mah et al. 
2010) and BRCA1 (breast cancer 1, for transcription associated DNA damage (Hill et al. 
2014, 2016)) in mouse tissues and will be applied to assess in which cell populations and at 
what time point DNA damage occurs in SMA and control mice. 
 
Figure 4.9. Resistant and vulnerable somatic motor neurons display distinct disease-induced 
transcriptional adaptation. (A) Somatic motor neurons regulated more genes in disease than unaffected 
control populations. (B) All somatic motor neurons displayed differential expression of genes related to 
DNA damage response and apoptosis pathways. Resistant CN3/4 neurons specifically up-regulated genes 
involved in synaptic transmission (Syt1, Syt5, Cplx2), regeneration (Gap43, Chl1) and up-regulated genes 
that protect from cellular stress (Pak4, Aldh4a1). Shared up-regulation of cytoskeleton-related transcripts 
(Inf2, Tubb6) in vulnerable SC and CN7 likely reflect axonal degeneration. Activation of Timeless 
expression could be a sign of exacerbated DNA damage in the most vulnerable SC motor neurons. 
P = postnatal day. No fold-change cutoff was applied and events with adjusted P<0.05 were considered 
significant. DEG = differentially expressed gene. 
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4.4.3 A vulnerability signature of spinal and facial motor neurons 
In our analysis that compared spinal motor neurons and those of CN3/4 we identified 
Timeless, which determined SC identity and had a strong influence on the genotype 
component due to its drastic up-regulation in these neurons in SMA. Timeless is indirectly 
linked to the p53 pathway through its important role during DNA replication (Gotter et al. 
2007) and it can furthermore mediate DNA damage repair after laser induced double strand 
breaks (Young et al. 2015). Along with the regulation of other numerous genes related to a 
DNA damage response, the strong up-regulation of Timeless only in SC could be a sign of 
exacerbated DNA damage in these cells. Both TIMELESS and FUS are recruited to sites of 
DNA damage in a PARP1- dependent manner (Rulten et al. 2014; Young et al. 2015) 
providing yet another link between mechanisms commonly activated in SMA and ALS. 
Other genes, which separated Smn1- deficient spinal motor neurons from the most 
resistant CN3/4 motor neurons were tubulin beta 6 (Tubb6) and Inf2. Interestingly, these were 
also up-regulated in the vulnerable CN7 motor neurons. Altered expression of INF2, which is 
a potent actin filament severing protein (Gurel et al. 2014), and other cytoskeletal 
components at P10 is likely a sign of axon degeneration in these two vulnerable populations 
(Figure 4.9B). 
4.4.4 Distinct SMA-induced transcriptional changes in resistant motor neurons 
Using gene ontology (GO) term enrichment analysis, we observed terms like ‘nervous system 
development’ and ‘generation of neurons’ in our resistant groups. We speculate that the 
regulation of these genes reflects degenerative/regenerative responses. Several of these GO 
term genes up-regulated in CN3/4, including Gap43 and Chl1, are also upregulated upon 
axon injury (Verhaagen et al. 1988; Zhang et al. 2000) supporting this notion. Moreover, it 
was recently shown that Gap43 mRNA and protein levels were reduced in axons and growth 
cones of primary spinal motor neurons isolated from a severe mouse model of SMA (Fallini 
et al. 2016). This could imply a lower capacity for re-connectivity of vulnerable cells. 
Additionally, through our analysis of CN3/4 versus SC motor neurons, we found that Syt1 
and Cplx2, which are also in the nervous system development term, had a strong weight on 
the genotype and cell type component. SYT1 and CPLX2 function in neurotransmitter 
release, which appears to be impaired in SMA (Kariya et al. 2008; Ruiz and Tabares 2014). 
Furthermore, SYT1 has recently been associated with differential vulnerability in SMA 
(Tejero et al. 2016). Their CN3/4 specific up-regulation together with other genes associated 
with regeneration likely presents a protective mechanism that could contribute to their 
resistance in SMA (Figure 4.9B). 
Investigation of the regenerative capacity of CN3/4 neurons will give us further 
insight into this hypothesis. Towards this goal, it will be interesting to investigate the 
presence of regeneration markers like GAP43 and CHL1 in the axons of these cells. 
Furthermore, axonal sprouting and the presence of growth cones can be easily assessed in 
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stained tissue sections. One has to keep in mind however, that such strategies may prove 
challenging due to the still ongoing remodeling of the NMJ during the first two postnatal 
weeks, which is likely accompanied by the aforementioned markers. The use of a milder 
SMA mouse model with longer survival is a possibility to circumvent these issues in such 
investigations. 
Furthermore, we would like to point out that there is no clear consensus if CN3/4 motor 
neurons belong to the group of somatic or visceral motor neurons. Motor neurons of the 
ocular motor system are undoubtedly distinct from other somatic motor neurons in several 
aspects. They differ in their electrophysiological properties, underlined by the unique 
characteristics of the muscles they innervate. Their transcriptome furthermore diverges from 
those of spinal and hypoglossal motor neurons as shown in rat, mouse and man. Our 
transcriptome analysis adds important pieces to the puzzle by demonstrating that CN3/4 
motor neurons are still closer to somatic motor neurons than visceral CN10 motor neurons. 
On the one hand, this is evidenced by higher correlation of the entire gene expression profiles 
in health. On the other hand, it is clear that adaptation mechanisms induced by SMN 
deficiency in CN3/4 are more similar to SC, CN7 and CN12 than to CN10 motor neurons. 
These findings furthermore highlight the value of using CN3/4 motor neurons as means of 
dissecting protective mechanisms that could be used to rescue vulnerable populations. 
Taken together, future studies evaluating gain- and loss-of-function of selected candidates are 
necessary that will provide further insight into their role in vulnerability and resistance. 
Through our transcriptome analysis of neuronal populations with differential vulnerability in 
SMA, we could dissect disease-induced changes that are common to all somatic motor 
neurons and thus aid in understanding general disease mechanisms. Moreover, we have 
identified cell type specific, potentially protective gene expression changes that might 
underlie the differential vulnerability of somatic motor neurons and could eventually lead to 
the development of therapeutic targets. 
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5 CONCLUSION 
Motor neuron diseases preferentially affect specific neuronal populations with distinct clinical 
features even if disease-causing genes are expressed across many cell types and tissues. In 
SMA, somatic motor neurons are selectively vulnerable to the loss of the broadly expressed 
SMN1 gene. In ALS, mutations in multiple ubiquitously expressed genes have been identified 
that result in the same selective vulnerability of somatic motor neurons. However, certain 
somatic motor neuron groups, including oculomotor and trochlear neurons, are for unknown 
reasons relatively resistant to degeneration. We hypothesized that we could use oculomotor 
resistance as a tool to dissect mechanisms of vulnerability and protection, which would aid in 
identifying drug targets for the treatment of so far incurable motor neuron diseases. The work 
presented in this thesis underlines the potential of this approach in several aspects: 
In paper I and II, we further investigated candidates with implications for differential 
vulnerability that have been identified in a previous transcriptome analysis comparing 
resistant and vulnerable motor neurons in the normal rat. Importantly, we demonstrated a 
relative conservation across species by confirming the expression patterns of multiple 
proteins in mouse and human and in health and disease. Moreover, we provide functional 
evidence that the oculomotor restricted factor IGF-2 can rescue vulnerable spinal motor 
neurons thus indicating that it could in part play a role in oculomotor preservation in ALS. To 
further pinpoint protective and detrimental mechanisms, it is important to understand how 
cell populations with differential vulnerability adapt to the same toxic genetic changes. In 
study III, we provide a robust and sensitive protocol for transcriptional profiling of closely 
related cell types that we applied in study IV in order to dissect disease mechanisms in six 
different neuronal populations in SMA. Our findings here highlight the value of using a 
closely related but resistant population as a control to further dissect general disease 
mechanisms from adaptations that could confer susceptibility and resistance. 
Taken together, we here provide a tool box for transcriptional profiling of neuronal 
populations with differential vulnerability followed by functional studies in mouse and 
human that could aid in elucidating pathological mechanisms in neurodegenerative diseases. 
  
 42 
 
 
  43 
6 ACKNOWLEDGEMENTS 
I have really been enjoying these last few years in Stockholm- I’ve had a wonderful time 
thanks to so many beautiful people! 
Eva, I am going to try and summarize just in a few simple words how much I appreciate 
having you as my supervisor: I want to thank you for letting me go bananas when I wanted 
to, for making me go bananas when I needed to and for stopping me from going bananas 
when I didn’t know what to do. And let’s not forget about all the bananas- because fruit 
baskets make this world a better place! THANK YOU! 
Another big thank you goes to Staffan, for filling the Cullheim/Hedlund Lab with his 
wisdom and calming the crazy bunch down when necessary! It’s been an honor to have you 
as my co-supervisor and I wish I had knocked on your door much more often because every 
time, I left it with a bit more knowledge and curiosity and many more ideas. 
Laura and Ilary, from the very beginning it’s been pure pleasure to have you as my post-
docs and I am not even gonna try and name any reasons here. Ok, maybe one… You guys 
absolutely, 100%, significantly (****) personally and scientifically rock! 
Julio and Jik, thank you for being great colleagues and friends, for being critical, happy and 
nerdy and for making the lab and office a place I like hanging out at every day! I am really 
hoping that after this defense, I can go shadow you to learn the secrets of generating a human 
motor neuron ;) 
Thank you, Mirjam and Rein, for keeping me out of the cold and the dark at least for a little 
while :) You’ve done a great job cutting and LCMing and it’s been great having you and your 
happy faces in the lab! 
A big hug and thank you to Anita for all your help! Even though you are in the meantime 
enjoying your well-deserved retirement, your happy soul is still present in the lab and smiling 
at me from the Kemi-cupboards, fridges and the Western bench :) 
Christina, Gillian, Johanna and Ming, it’s been fun to have you around and I want to say 
thanks also to you for making the lab such a happy and at the same time productive place! 
 
 44 
You are not quite lab members, Giada, Ste, Sal, Caitlin, Yvonne, Mike, Paul, you are more 
like family. You are wonderful happy people and you have made me feel at home in 
Stockholm (and on the 5th floor in the neuro department :)) from day one! TACK! 
I want to thank Rickard and the Sandberg crew, for sharing your expertise and advice, for 
sharing your RNA sequencer and reagents and most of all for sharing Helena- what would I 
have done without her? I’d probably still be sitting somewhere in a basement trying to figure 
out bioinformatics… Thanks for not assigning me to your spam folder, although I bet you 
were tempted at times :D Stor tack! 
Qiaolin, you have all my gratitude for patiently teaching me everything about prepping 
sequencing libraries and for your contagious ambitious attitude. I have learned a lot! Thanks 
for temporarily joint lab meetings and for a great collaboration especially to Marlene and 
Geng. Go Team Hedlund/Deng! 
I am also happy to be collaborating with Stefania Corti’s lab in Milan- thank you for all 
your amazing work and for your extraordinary hospitality during our visits! We are still 
waiting for you here in Stockholm and, just saying, summer is approaching :) 
I would like to thank the Frisén lab for letting me use their LCM: special thanks go to Marta 
for always being helpful and fixing problems right away! Tack! 
Even though it’s been a while now, I will never forget the happy chats that covered the noise 
of the cell culture hoods (or the lunch room!!) thanks to the Hermanson crew; most of all 
Aileen, Esra, Giulia and Michalina, you ladies rock! 
A big thank you to Peter and Kuba, and also Anders from KIB, for your prompt help with 
last minute printing issues... I really appreciate it! Stor tack! 
Thanks to Marc Ruepp- for sharing your Western Blotting wisdom with me, Bjerrum buffer 
rocks! And thank you to the whole Ruepp Lab for fun times at the one or other occasion. 
Special thanks to Mr Selecta, you inspired me to write a song! And who knows, maybe I will 
one day follow my destiny and become a rap star… And while I am on it, I here want to 
thank ‘The XX’ for composing these two beautiful albums that kept me company during so 
many otherwise lonely hours at the LCM (and my sincere apologies to the people next doors 
who had to listen to the same music over and over again!). 
I also want to mention the probably biggest contributors… the sweet little mice. Although not 
always cooperative (…), you have totally made this thesis. Would have never happened 
  45 
without you! I promise to always stick to the four R’s: replace, reduce, refine and r… the data 
until there is really nothing to learn from it anymore (I should be busy with that for a little 
while longer). 
Danke an meine lieben Eltern, die mir all das hier überhaupt ermöglicht haben mit ihrer 
steten Unterstützung! Ich will euch hier nochmal besonders dafür danken, dass ihr mich nach 
meinem Australien Trip als 29-jährige wieder in mein Kinderzimmer gelassen habt. Ohne 
eure Geduld hätte ich wohl nie so viel Zeit auf der KI Homepage verbracht, um dieses 
Projekt zu entdecken…! Tack :) 
Pawel, it feels a little silly to say thank you to you here as I am telling you probably every 
single day how grateful I am to have you by my side and how much I appreciate our midnight 
science discussions especially these past few months! Even if this thesis work should not 
contribute to the continuation of my scientific career and the selecta song won’t make it to the 
charts and earn us millions, I am sure to not leave this chapter empty handed; thanks to this 
beautiful little ring that you put on my finger :) 
 

  47 
7 REFERENCES 
 
Acsadi G, Lee I, Li X, Khaidakov M, Pecinova A, Parker GC, Huttemann M. 2009. Mitochondrial 
dysfunction in a neural cell model of spinal muscular atrophy. J Neurosci Res 87: 2748–2756. 
Ahmadi M, Liu JX, Brännström T, Andersen PM, Stål P, Pedrosa-Domellöf F. 2010. Human 
extraocular muscles in ALS. Investig Ophthalmol Vis Sci 51: 3494–3501. 
Allodi I, Hedlund E. 2014. Directed midbrain and spinal cord neurogenesis from pluripotent stem 
cells to model development and disease in a dish. Front Neurosci. 
An T, Shi P, Duan W, Zhang S, Yuan P, Li Z, Wu D, Xu Z, Li C, Guo Y. 2014. Oxidative Stress 
and Autophagic Alteration in Brainstem of SOD1-G93A Mouse Model of ALS. Mol 
Neurobiol 49: 1435–1448. 
Anderson DM, Cannavino J, Li H, Anderson KM, Nelson BR, McAnally J, Bezprozvannaya S, Liu 
Y, Lin W, Liu N, et al. 2016. Severe muscle wasting and denervation in mice lacking the 
RNA-binding protein ZFP106. Proc Natl Acad Sci U S A 113: E4494-503. 
Balabanian S, Gendron NH, MacKenzie AE. 2007. Histologic and transcriptional assessment of a 
mild SMA model. Neurol Res 29: 413–424. 
Bandyopadhyay U, Cotney J, Nagy M, Oh S, Leng J, Mahajan M, Mane S, Fenton WA, Noonan JP, 
Horwich AL. 2013. RNA-Seq Profiling of Spinal Cord Motor Neurons from a Presymptomatic 
SOD1 ALS Mouse. PLoS One 8. 
Bäumer D, Lee S, Nicholson G, Davies JL, Parkinson NJ, Murray LM, Gillingwater TH, Ansorge 
O, Davies KE, Talbot K. 2009. Alternative splicing events are a late feature of pathology in a 
mouse model of spinal muscular atrophy. PLoS Genet 5. 
Bilsland LG, Sahai E, Kelly G, Golding M, Greensmith L, Schiavo G. 2010. Deficits in axonal 
transport precede ALS symptoms in vivo. Proc Natl Acad Sci U S A 107: 20523–20528. 
Boillée S, Yamanaka K, Lobsiger CS, Copeland NG, Jenkins N a, Kassiotis G, Kollias G, 
Cleveland DW. 2006. Onset and progression in inherited ALS determined by motor neurons 
and microglia. Science 312: 1389–1392. 
Bowerman M, Shafey D, Kothary R. 2007. Smn depletion alters profilin II expression and leads to 
upregulation of the RhoA/ROCK pathway and defects in neuronal integrity. J Mol Neurosci 
32: 120–131. 
Braughler JM, Hall ED. 1982. Correlation of methylprednisolone levels in cat spinal cord with its 
effects on (Na+ + K+)-ATPase, lipid peroxidation, and alpha motor neuron function. J 
Neurosurg 56: 838–44. 
Briese M, Saal L, Appenzeller S, Moradi M, Baluapuri A, Sendtner M. 2015. Whole transcriptome 
profiling reveals the RNA content of motor axons. Nucleic Acids Res 44. 
Brockington A, Ning K, Heath PR, Wood E, Kirby J, Fusi N, Lawrence N, Wharton SB, Ince PG, 
Shaw PJ. 2013. Unravelling the enigma of selective vulnerability in neurodegeneration: Motor 
neurons resistant to degeneration in ALS show distinct gene expression characteristics and 
decreased susceptibility to excitotoxicity. Acta Neuropathol 125: 95–109. 
Bruijn LI, Becher MW, Lee MK, Anderson KL, Jenkins NA, Copeland NG, Sisodia SS, Rothstein 
JD, Borchelt DR, Price DL, et al. 1997. ALS-linked SOD1 mutant G85R mediates damage to 
astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 
18: 327–338. 
Bussaglia E, Clermont O, Tizzano E, Lefebvre S, Burglen L, Cruaud C, Urtizberea JA, Colomer J, 
Munnich A, Baiget M, et al. 1995. A frame-shift deletion in the survival motor neuron gene in 
Spanish spinal muscular atrophy patients. Nat Genet 11: 335–7. 
Caligari M, Godi M, Guglielmetti S, Franchignoni F, Nardone A. 2013. Eye tracking 
communication devices in amyotrophic lateral sclerosis: impact on disability and quality of 
life. Amyotroph Lateral Scler Frontotemporal Degener 14: 546–52. 
Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, 
Bennett CF, Bishop KM. 2016. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in 
children with spinal muscular atrophy. Neurology 86: 890–7. 
Cifuentes-Diaz C, Frugier T, Tiziano FD, Lacène E, Roblot N, Joshi V, Moreau MH, Melki J. 2001. 
Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular 
dystrophy. J Cell Biol 152: 1107–1114. 
Cifuentes-Diaz C, Nicole S, Velasco ME, Borra-Cebrian C, Panozzo C, Frugier T, Millet G, Roblot 
 48 
N, Joshi V, Melki J. 2002. Neurofilament accumulation at the motor endplate and lack of 
axonal sprouting in a spinal muscular atrophy mouse model. Hum Mol Genet 11: 1439–1447. 
Comley LH, Nijssen J, Frost-Nylen J, Hedlund E. 2016. Cross-disease comparison of amyotrophic 
lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but 
differential neuromuscular junction pathology. J Comp Neurol 524: 1424–1442. 
Corti S, Nizzardo M, Simone C, Falcone M, Nardini M, Ronchi D, Donadoni C, Salani S, Riboldi 
G, Magri F, et al. 2012. Genetic correction of human induced pluripotent stem cells from 
patients with spinal muscular atrophy. Sci Transl Med 4: 165ra162. 
Cullheim S, Fleshman JW, Glenn LL, Burke RE. 1987. Three-Dimensional architecture of dendritic 
trees in type-identified alpha-motoneurons. J Comp Neurol 255: 82–96. 
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, Nicholson 
AM, Finch NCA, Flynn H, Adamson J, et al. 2011. Expanded GGGGCC Hexanucleotide 
Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. 
Neuron 72: 245–256. 
Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. 2007. Non-cell autonomous effect of 
glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 10: 608–14. 
Dobrowolny G, Aucello M, Rizzuto E, Beccafico S, Mammucari C, Boncompagni S, Belia S, 
Wannenes F, Nicoletti C, Del Prete Z, et al. 2008. Skeletal Muscle Is a Primary Target of 
SOD1G93A-Mediated Toxicity. Cell Metab 8: 425–436. 
Doktor TK, Hua Y, Andersen HS, Brøner S, Liu YH, Wieckowska A, Dembic M, Bruun GH, 
Krainer AR, Andresen BS. 2016. RNA-sequencing of a mouse-model of spinal muscular 
atrophy reveals tissue-wide changes in splicing of U12-dependent introns. Nucleic Acids Res 
gkw731. 
Ebert AD, Yu J, Rose FF, Mattis VB, Lorson CL, Thomson JA, Svendsen CN. 2009. Induced 
pluripotent stem cells from a spinal muscular atrophy patient. Nature 457: 277–80. 
Edens BM, Ajroud-Driss S, Ma L, Ma Y. 2015. Molecular mechanisms and animal models of spinal 
muscular atrophy. Biochim Biophys Acta 1852: 685–92. 
Eustache I, Seyfritz N, Gueritaud JP. 1994. Effects of insulin-like growth factors on organotypic 
cocultures of embryonic rat brainstem slices and skeletal muscle fibers. Brain Res Dev Brain 
Res 81: 284–292. 
Fallini C, Bassell GJ, Rossoll W. 2010. High-efficiency transfection of cultured primary motor 
neurons to study protein localization, trafficking, and function. Mol Neurodegener 5: 17. 
Fallini C, Donlin-Asp PG, Rouanet JP, Bassell GJ, Rossoll W. 2016. Deficiency of the Survival of 
Motor Neuron Protein Impairs mRNA Localization and Local Translation in the Growth Cone 
of Motor Neurons. J Neurosci 36: 3811–20. 
Fan L, Simard LR. 2002. Survival motor neuron (SMN) protein: role in neurite outgrowth and 
neuromuscular maturation during neuronal differentiation and development. Hum Mol Genet 
11: 1605–1614. 
Ferraiuolo L, Heath PR, Holden H, Kasher P, Kirby J, Shaw PJ. 2007. Microarray analysis of the 
cellular pathways involved in the adaptation to and progression of motor neuron injury in the 
SOD1 G93A mouse model of familial ALS. J Neurosci 27: 9201–19. 
Ferraiuolo L, Kirby J, Grierson  a J, Sendtner M, Shaw PJ. 2011. Molecular pathways of motor 
neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol 7: 616–630. 
Ferrucci M, Spalloni A, Bartalucci A, Cantafora E, Fulceri F, Nutini M, Longone P, Paparelli A, 
Fornai F. 2010. A systematic study of brainstem motor nuclei in a mouse model of ALS, the 
effects of lithium. Neurobiol Dis 37: 370–383. 
Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, Yamashita M, Rigo F, Hung 
G, Schneider E, et al. 2017. Treatment of infantile-onset spinal muscular atrophy with 
nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388: 3017–3026. 
Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, 
Glass JD. 2004. Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and 
man. Exp Neurol 185: 232–240. 
Freibaum BD, Lu Y, Lopez-Gonzalez R, Kim NC, Almeida S, Lee K-H, Badders N, Valentine M, 
Miller BL, Wong PC, et al. 2015. GGGGCC repeat expansion in C9orf72 compromises 
nucleocytoplasmic transport. Nature 525: 129–133. 
Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. 2000. Early and selective loss of 
neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J 
  49 
Neurosci 20: 2534–42. 
Gabanella F, Butchbach MER, Saieva L, Carissimi C, Burghes AHM, Pellizzoni L. 2007. 
Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and 
preferentially affect a subset of spliceosomal snRNPs. PLoS One 2. 
Gitcho MA, Baloh RH, Chakraverty S, Mayo K, Norton JB, Levitch D, Hatanpaa KJ, White CL, 
Bigio EH, Caselli R, et al. 2008. TDP-43 A315T mutation in familial motor neuron disease. 
Ann Neurol 63: 535–538. 
Gizzi M, DiRocco A, Sivak M, Cohen B. 1992. Ocular motor function in motor neuron disease. 
Neurology 42: 1037–46. 
Gnesutta N, Minden A. 2003. Death receptor-induced activation of initiator caspase 8 is 
antagonized by serine/threonine kinase PAK4. Mol Cell Biol 23: 7838–48. 
Gnesutta N, Qu J, Minden A. 2001. The Serine/Threonine Kinase PAK4 Prevents Caspase 
Activation and Protects Cells from Apoptosis. J Biol Chem 276: 14414–14419. 
Gotter AL, Suppa C, Emanuel BS. 2007. Mammalian TIMELESS and Tipin are Evolutionarily 
Conserved Replication Fork-associated Factors. J Mol Biol 366: 36–52. 
Groen EJN, Fumoto K, Blokhuis AM, Engelen-Lee JY, Zhou Y, van den Heuvel DMA, Koppers 
M, van Diggelen F, van Heest J, Demmers JAA, et al. 2013. ALS-associated mutations in FUS 
disrupt the axonal distribution and function of SMN. Hum Mol Genet 22: 3690–3704. 
Guerrero EN, Wang H, Mitra J, Hegde PM, Stowell SE, Liachko NF, Kraemer BC, Garruto RM, 
Rao KS, Hegde ML. 2016. TDP-43/FUS in motor neuron disease: Complexity and challenges. 
Prog Neurobiol 145–146: 78–97. 
Gurel PS, Ge P, Grintsevich EE, Shu R, Blanchoin L, Zhou ZH, Reisler E, Higgs HN. 2014. Article 
INF2-Mediated Severing through Actin Filament Encirclement and Disruption. Curr Biol 24: 
156–164. 
Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, 
Kwon YW, Deng HX, et al. 1994. Motor neuron degeneration in mice that express a human 
Cu,Zn superoxide dismutase mutation. Science 264: 1772–5. 
Hadzipasic M, Tahvildari B, Nagy M, Bian M, Horwich AL, McCormick DA. 2014. Selective 
degeneration of a physiological subtype of spinal motor neuron in mice with SOD1-linked 
ALS. Proc Natl Acad Sci U S A 111: 16883–16888. 
Haenggeli C, Kato AC. 2002. Differential vulnerability of cranial motoneurons in mouse models 
with motor neuron degeneration. Neurosci Lett 335: 39–43. 
Haidet-Phillips AM, Hester ME, Miranda CJ, Meyer K, Braun L, Frakes A, Song S, Likhite S, 
Murtha MJ, Foust KD, et al. 2011. Astrocytes from familial and sporadic ALS patients are 
toxic to motor neurons. Nat Biotech 29: 824–828. 
Hall ED, Oostveen JA, Gurney ME. 1998. Relationship of microglial and astrocytic activation to 
disease onset and progression in a transgenic model of familial ALS. Glia 23: 249–256. 
Hamilton G, Gillingwater TH. 2013. Spinal muscular atrophy: Going beyond the motor neuron. 
Trends Mol Med 19: 40–50. 
Harding BN, Kariya S, Monani UR, Chung WK, Benton M, Yum SW, Tennekoon G, Finkel RS. 
2015. Spectrum of neuropathophysiology in spinal muscular atrophy type I. J Neuropathol 
Exp Neurol 74: 15–24. 
Hedlund E, Karlsson M, Osborn T, Ludwig W, Isacson O. 2010. Global gene expression profiling 
of somatic motor neuron populations with different vulnerability identify molecules and 
pathways of degeneration and protection. Brain 133: 2313–2330. 
Henkel JS, Engelhardt JI, Siklos L, Simpson EP, Kim SH, Pan T. 2004. Presence of dendritic cells, 
MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord 
tissue. Ann Neurol 55. 
Hensley K, Abdel-Moaty H, Hunter J, Mhatre M, Mou S, Nguyen K, Potapova T, Pye QN, Qi M, 
Rice H, et al. 2006. Primary glia expressing the G93A-SOD1 mutation present a 
neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation. 
J Neuroinflammation 3: 1–9. 
Hill SJ, Mordes DA, Cameron LA, Neuberg DS, Landini S, Eggan K, Livingston DM. 2016. Two 
familial ALS proteins function in prevention/repair of transcription-associated DNA damage. 
Proc Natl Acad Sci U S A 201611673. 
Hill SJ, Rolland T, Adelmant G, Xia X, Owen MS, Dricot A, Zack TI, Sahni N, Jacob Y, Hao T, et 
al. 2014. Systematic screening reveals a role for BRCA1 in the response to transcription-
 50 
associated DNA damage. Genes Dev 28: 1957–1975. 
Howland DS, Liu J, She Y, Goad B, Maragakis NJ, Kim B, Erickson J, Kulik J, DeVito L, Psaltis 
G, et al. 2002. Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of 
SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A 99: 
1604–1609. 
Hunter G, Aghamaleky Sarvestany A, Roche SL, Symes RC, Gillingwater TH. 2013. SMN-
dependent intrinsic defects in Schwann cells in mouse models of spinal muscular atrophy. 
Hum Mol Genet 1–16. 
Iyer CC, McGovern VL, Murray JD, Gombash SE, Zaworski PG, Foust KD, Janssen PML, Burghes 
AHM. 2015. Low levels of Survival Motor Neuron protein are sufficient for normal muscle 
function in the SMNdelta7 mouse model of SMA. Hum Mol Genet 24: 6160–6173. 
Jablonka S, Bandilla M, Wiese S, Bühler D, Wirth B, Sendtner M, Fischer U. 2001. Co-regulation 
of survival of motor neuron (SMN) protein and its interactor SIP1 during development and in 
spinal muscular atrophy. Hum Mol Genet 10: 497–505. 
Jablonka S, Schrank B, Kralewski M, Rossoll W, Sendtner M. 2000. Reduced survival motor 
neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for 
spinal muscular atrophy type III. Hum Mol Genet 9: 341–6. 
Jovičić A, Mertens J, Boeynaems S, Bogaert E, Chai N, Yamada SB, Paul JW, Sun S, Herdy JR, 
Bieri G, et al. 2015. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic 
transport defects to FTD/ALS. Nat Neurosci 18: 1226–9. 
Joyce PI, Fratta P, Landman AS, Mcgoldrick P, Wackerhage H, Groves M, Busam BS, Galino J, 
Corrochano S, Beskina OA, et al. 2016. Deficiency of the zinc finger protein ZFP106 causes 
motor and sensory neurodegeneration. Hum Mol Genet 25: 291–307. 
Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, 
Lacomblez L, Pochigaeva K, Salachas F, et al. 2008. TARDBP mutations in individuals with 
sporadic and familial amyotrophic lateral sclerosis. Nat Genet 40: 572–574. 
Kadkhodaei B, Alvarsson A, Schintu N, Ramsköld D, Volakakis N, Joodmardi E, Yoshitake T, 
Kehr J, Decressac M, Björklund A, et al. 2013. Transcription factor Nurr1 maintains fiber 
integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc Natl 
Acad Sci U S A 110: 2360–5. 
Kang SH, Li Y, Fukaya M, Lorenzini I, Cleveland DW, Ostrow LW, Rothstein JD, Bergles DE. 
2013. Degeneration and impaired regeneration of gray matter oligodendrocytes in amyotrophic 
lateral sclerosis. Nat Neurosci 16: 571–9. 
Kaplan A, Spiller KJ, Towne C, Kanning KC, Choe GT, Geber A, Akay T, Aebischer P, Henderson 
CE. 2014. Neuronal matrix Metalloproteinase-9 is a determinant of selective 
Neurodegeneration. Neuron 81: 333–348. 
Kariya S, Obis T, Garone C, Akay T, Sera F, Iwata S, Homma S, Monani UR. 2014. Requirement 
of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation. 
J Clin Invest 124: 785–800. 
Kariya S, Park GH, Maeno-Hikichi Y, Leykekhman O, Lutz C, Arkovitz MS, Landmesser LT, 
Monani UR. 2008. Reduced SMN protein impairs maturation of the neuromuscular junctions 
in mouse models of spinal muscular atrophy. Hum Mol Genet 17: 2552–2569. 
Kashlan ON, Kashlan BN, Oh SS, McGinley LM, Chen KS, Kupfer R, Erman A, Sakowski SA, 
Feldman EL. 2015. Histological bulbar manifestations in the ALS rat. Neurodegener Dis 15: 
121–126. 
Ketterer C, Zeiger U, Budak MT, Rubinstein NA, Khurana TS. 2010. Identification of the 
neuromuscular junction transcriptome of extraocular muscle by laser capture microdissection. 
Investig Ophthalmol Vis Sci 51: 4589–4599. 
Khosravi B, Hartmann H, May S, Möhl C, Ederle H, Michaelsen M, Schludi MH, Dormann D, 
Edbauer D. 2016. Cytoplasmic poly-GA aggregates impair nuclear import of TDP-43 in 
C9orf72 ALS/FTLD. Hum Mol Genet 0: ddw432. 
Kiaei M, Kipiani K, Calingasan NY, Wille E, Chen J, Heissig B, Rafii S, Lorenzl S, Beal MF. 2007. 
Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells 
and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp 
Neurol 205: 74–81. 
Kiskinis E, Sandoe J, Williams LA, Boulting GL, Moccia R, Wainger BJ, Han S, Peng T, Thams S, 
Mikkilineni S, et al. 2014. Pathways disrupted in human ALS motor neurons identified 
  51 
through genetic correction of mutant SOD1. Cell Stem Cell 14: 781–795. 
Koppers M, Blokhuis AM, Westeneng HJ, Terpstra ML, Zundel CAC, Vieira De Sá R, Schellevis 
RD, Waite AJ, Blake DJ, Veldink JH, et al. 2015. C9orf72 ablation in mice does not cause 
motor neuron degeneration or motor deficits. Ann Neurol 78: 426–438. 
Kubota M, Sakakihara Y, Uchiyama Y, Nara A, Nagata T, Nitta H, Ishimoto K, Oka A, Horio K, 
Yanagisawa M. 2000. New ocular movement detector system as a communication tool in 
ventilator-assisted Werdnig-Hoffmann disease. Dev Med Child Neurol 42: 61–4. 
Kwiatkowski TJ, Bosco DA, Leclerc AL, Tamrazian E, Vanderburg CR, Russ C, Davis A, Gilchrist 
J, Kasarskis EJ, Munsat T, et al. 2009. Mutations in the FUS/TLS gene on chromosome 16 
cause familial amyotrophic lateral sclerosis. Science 323: 1205–8. 
Lagier-Tourenne C, Polymenidou M, Hutt KR, Vu AQ, Baughn M, Huelga SC, Clutario KM, Ling 
S-C, Liang TY, Mazur C, et al. 2012. Divergent roles of ALS-linked proteins FUS/TLS and 
TDP-43 intersect in processing long pre-mRNAs. Nat Neurosci 15: 1488–1497. 
Le TT, Pham LT, Butchbach MER, Zhang HL, Monani UR, Coovert DD, Gavrilina TO, Xing L, 
Bassell GJ, Burghes AHM. 2005. SMNΔ7, the major product of the centromeric survival 
motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and 
associates with full-length SMN. Hum Mol Genet 14: 845–857. 
Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, 
Millasseau P, Zeviani M, et al. 1995. Identification and characterization of a spinal muscular 
atrophy-determining gene. Cell 80: 155–165. 
Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, 
Brockway KS, Byrnes EJ, et al. 2007. Genome-wide atlas of gene expression in the adult 
mouse brain. Nature 445: 168–176. 
Lewin B. 2008. Genes IX. 9th editio. Jones & Bartlett Learning. 
Lim GP, Backstrom JR, Cullen MJ, Miller CA, Atkinson RD, Tökés ZA. 1996. Matrix 
metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J 
Neurochem 67: 251–259. 
Liu Q, Dreyfuss G. 1996. A novel nuclear structure containing the survival of motor neurons 
protein. EMBO J 15: 3555–3565. 
Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, Yachnis AT, Ranum LPW. 2016. 
C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of 
ALS/FTD. Neuron 90: 521–534. 
Lobsiger CS, Boillée S, Cleveland DW. 2007. Toxicity from different SOD1 mutants dysregulates 
the complement system and the neuronal regenerative response in ALS motor neurons. Proc 
Natl Acad Sci U S A 104: 7319–26. 
Lu C-H, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, 
Sidle K, Fish M, et al. 2015. Neurofilament light chain: A prognostic biomarker in 
amyotrophic lateral sclerosis. Neurology 84: 2247–2257. 
Lu CH, Petzold A, Kalmar B, Dick J, Malaspina A, Greensmith L. 2012. Plasma neurofilament 
heavy chain levels correlate to markers of late stage disease progression and treatment 
response in SOD1G93A mice that model ALS. PLoS One 7. 
Maeda M, Harris AW, Kingham BF, Lumpkin CJ, Opdenaker LM, Mccahan SM, Wang W, 
Butchbach MER. 2014. Transcriptome profiling of spinal muscular atrophy motor neurons 
derived from mouse embryonic stem cells. PLoS One 9. 
Mah L-J, El-Osta A, Karagiannis TC. 2010. gammaH2AX: a sensitive molecular marker of DNA 
damage and repair. Leuk  Off J Leuk Soc Am Leuk Res Fund, UK 24: 679–686. 
Mancuso R, Oliván S, Mancera P, Pastén-Zamorano A, Manzano R, Casas C, Osta R, Navarro X. 
2012. Effect of genetic background on onset and disease progression in the SOD1-G93A 
model of amyotrophic lateral sclerosis. Amyotroph Lateral Scler 13: 302–310. 
Marchetto MCN, Muotri AR, Mu Y, Smith AM, Cezar GG, Gage FH. 2008. Non-cell-autonomous 
effect of human SOD1 G37R astrocytes on motor neurons derived from human embryonic 
stem cells. Cell Stem Cell 3: 649–657. 
Martinez TL, Kong L, Wang X, Osborne MA, Crowder ME, Van Meerbeke JP, Xu X, Davis C, 
Wooley J, Goldhamer DJ, et al. 2012. Survival motor neuron protein in motor neurons 
determines synaptic integrity in spinal muscular atrophy. J Neurosci 32: 8703–15. 
Matsumoto K, Nishihara S, Kamimura M, Shiraishi T, Otoguro T, Uehara M, Maeda Y, Ogura K, 
Lumsden A, Ogura T. 2004. The prepattern transcription factor Irx2, a target of the 
 52 
FGF8/MAP kinase cascade, is involved in cerebellum formation. Nat Neurosci 7: 605–612. 
McGovern VL, Iyer CC, David Arnold W, Gombash SE, Zaworski PG, Blatnik AJ, Foust KD, 
Burghes AHM. 2015. SMN expression is required in motor neurons to rescue 
electrophysiological deficits in the SMNdelta7 mouse model of SMA. Hum Mol Genet 24: 
5524–5541. 
Mentis GZ, Blivis D, Liu W, Drobac E, Crowder ME, Kong L, Alvarez FJ, Sumner CJ, O’Donovan 
MJ. 2011. Early Functional Impairment of Sensory-Motor Connectivity in a Mouse Model of 
Spinal Muscular Atrophy. Neuron 69: 453–467. 
Meyer K, Ferraiuolo L, Miranda CJ, Likhite S, McElroy S, Renusch S, Ditsworth D, Lagier-
Tourenne C, Smith RA, Ravits J, et al. 2014. Direct conversion of patient fibroblasts 
demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and 
sporadic ALS. Proc Natl Acad Sci U S A 111: 829–32. 
Miller N, Shi H, Zelikovich AS, Ma Y-C. 2016. Motor Neuron Mitochondrial Dysfunction in Spinal 
Muscular Atrophy. Hum Mol Genet 0: 1–12. 
Miller RG, Mitchell JD, H MD, Moore DH. 2012. Riluzole for amyotrophic lateral sclerosis (ALS)/ 
motor neuron disease (MND). Cochrane Database Syst Rev 3: 191–206. 
Miller TM, Kim SH, Yamanaka K, Hester M, Umapathi P, Arnson H, Rizo L, Mendell JR, Gage 
FH, Cleveland DW, et al. 2006. Gene transfer demonstrates that muscle is not a primary target 
for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis. Proc Natl Acad Sci 
U S A 103: 19546–19551. 
Mitchell JC, McGoldrick P, Vance C, Hortobagyi T, Sreedharan J, Rogelj B, Tudor EL, Smith BN, 
Klasen C, Miller CCJ, et al. 2013. Overexpression of human wild-type FUS causes 
progressive motor neuron degeneration in an age- and dose-dependent fashion. Acta 
Neuropathol 125: 273–288. 
Mizuno T, Kurotani T, Komatsu Y, Kawanokuchi J, Kato H, Mitsuma N, Suzumura A. 2004. 
Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced 
by activated microglia. Neuropharmacology 46: 404–411. 
Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AHM, McPherson JD. 
1999. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene 
SMN1 from the copy gene SMN2. Hum Mol Genet 8: 1177–1183. 
Monani UR, Sendtner M, Coovert DD, Parsons DW, Andreassi C, Le TT, Jablonka S, Schrank B, 
Rossoll W, Prior TW, et al. 2000. The human centromeric survival motor neuron gene 
(SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal 
muscular atrophy. Hum Mol Genet 9: 333–339. 
Mori K, Weng S-M, Arzberger T, May S, Rentzsch K, Kremmer E, Schmid B, Kretzschmar HA, 
Cruts M, Broeckhoven C Van, et al. 2013. The C9orf72 GGGGCC Repeat Is Translated into 
Aggregating Dipeptide-Repeat Proteins in FTLD/ALS. Science (80- ) 339: 1335–1338. 
Murray LM, Beauvais A, Gibeault S, Courtney NL, Kothary R. 2015. Transcriptional profiling of 
differentially vulnerable motor neurons at pre-symptomatic stage in the Smn (2b/-) mouse 
model of spinal muscular atrophy. Acta Neuropathol Commun 3: 55. 
Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH. 2008. Selective 
vulnerability of motor neurons and dissociation of pre- and post-synaptic pathology at the 
neuromuscular junction in mouse models of spinal muscular atrophy. Hum Mol Genet 17: 
949–962. 
Murray LM, Lee S, Baumer D, Parson SH, Talbot K, Gillingwater TH. 2010. Pre-symptomatic 
development of lower motor neuron connectivity in a mouse model of severe spinal muscular 
atrophy. Hum Mol Genet 19: 420–433. 
Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, Przedborski S. 2007. 
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor 
neurons. Nat Neurosci 10: 615–22. 
Ng SY, Soh BS, Rodriguez-Muela N, Hendrickson DG, Price F, Rinn JL, Rubin LL. 2015. 
Genome-wide RNA-Seq of Human Motor Neurons Implicates Selective ER Stress Activation 
in Spinal Muscular Atrophy. Cell Stem Cell 17: 569–584. 
Nimchinsky EA, Young WG, Yeung G, Shah RA, Gordon JW, Bloom FE, Morrison JH, Hof PR. 
1999. Differential vulnerability of oculomotor, facial, and hypoglossal nuclei in G86R 
superoxide dismutase transgenic mice. J Comp Neurol 416: 112–125. 
O’Meara RW, Cummings SE, De Repentigny Y, McFall E, Michalski J-P, Deguise M-O, Gibeault 
  53 
S, Kothary R. 2017. Oligodendrocyte development and CNS myelination are unaffected in a 
mouse model of severe spinal muscular atrophy. Hum Mol Genet 0: ddw385. 
Patten S a, Armstrong G a B, Lissouba A, Kabashi E, Parker JA, Drapeau P. 2014. Fishing for 
causes and cures of motor neuron disorders. Dis Model Mech 7: 799–809. 
Pellizzoni L, Charroux B, Rappsilber J, Mann M, Dreyfuss G. 2001. A functional interaction 
between the survival motor neuron complex and RNA polymerase II. J Cell Biol 152: 75–85. 
Perera ND, Sheean RK, Crouch PJ, White AR, Horne MK, Turner BJ, Turner B. 2016. Enhancing 
survival motor neuron expression extends lifespan and attenuates neurodegeneration in mutant 
TDP-43 mice. Hum Mol Genet 0: ddw247. 
Peters OM, Ghasemi M, Brown RH. 2015. Emerging mechanisms of molecular pathology in ALS. J 
Clin Invest 125: 1767–1779. 
Petit F, Cuisset JM, Rouaix-Emery N, Cances C, Sablonniere B, Bieth E, Moerman A, Sukno S, 
Hardy N, Holder-Espinasse M, et al. 2011. Insights into genotype-phenotype correlations in 
spinal muscular atrophy: A retrospective study of 103 patients. Muscle and Nerve 43: 26–30. 
Picelli S, Björklund ÅK, Faridani OR, Sagasser S, Winberg G, Sandberg R. 2013. Smart-seq2 for 
sensitive full-length transcriptome profiling in single cells. Nat Methods 10: 1096–8. 
Polymenidou M, Lagier-Tourenne C, Hutt KR, Huelga SC, Moran J, Liang TY, Ling S-C, Sun E, 
Wancewicz E, Mazur C, et al. 2011. Long pre-mRNA depletion and RNA missplicing 
contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 14: 459–468. 
Pun S, Santos AF, Saxena S, Xu L, Caroni P. 2006. Selective vulnerability and pruning of phasic 
motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci 9: 408–419. 
Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, Schymick JC, 
Laaksovirta H, van Swieten JC, Myllykangas L, et al. 2011. A hexanucleotide repeat 
expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72: 257–
268. 
Rindt H, Feng Z, Mazzasette C, Glascock JJ, Valdivia D, Pyles N, Crawford TO, Swoboda KJ, 
Patitucci TN, Ebert AD, et al. 2015. Astrocytes influence the severity of spinal muscular 
atrophy. Hum Mol Genet 24: 4094–4102. 
Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, 
O’Regan JP, Deng HX. 1993. Mutations in Cu/Zn superoxide dismutase gene are associated 
with familial amyotrophic lateral sclerosis. Nature 362: 59–62. 
Rossoll W, Jablonka S, Andreassi C, Kröning AK, Karle K, Monani UR, Sendtner M. 2003. Smn, 
the spinal muscular atrophy-determining gene product, modulates axon growth and 
localization of β-actin mRNA in growth cones of motoneurons. J Cell Biol 163: 801–812. 
Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. 1995. Selective loss of glial 
glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 38: 73–84. 
Rudnik-Schöneborn S, Berg C, Zerres K, Betzler C, Grimm T, Eggermann T, Eggermann K, Wirth 
R, Wirth B, Heller R. 2009. Genotype-phenotype studies in infantile spinal muscular atrophy 
(SMA) type I in Germany: Implications for clinical trials and genetic counselling. Clin Genet 
76: 168–178. 
Ruggiu M, McGovern VL, Lotti F, Saieva L, Li DK, Kariya S, Monani UR, Burghes AHM, 
Pellizzoni L. 2012. A role for SMN exon 7 splicing in the selective vulnerability of motor 
neurons in spinal muscular atrophy. Mol Cell Biol 32: 126–38. 
Ruiz R, Tabares L. 2014. Neurotransmitter release in motor nerve terminals of a mouse model of 
mild spinal muscular atrophy. J Anat 224: 74–84. 
Rulten SL, Rotheray A, Green RL, Grundy GJ, Moore DAQ, Gomez-Herreros F, Hafezparast M, 
Caldecott KW. 2014. PARP-1 dependent recruitment of the amyotrophic lateral sclerosis-
associated protein FUS/TLS to sites of oxidative DNA damage. Nucleic Acids Res 42: 307–
314. 
Saal L, Briese M, Kneitz S, Glinka M, Sendtner M. 2014. Subcellular transcriptome alterations in a 
cell culture model of spinal muscular atrophy point to widespread defects in axonal growth 
and presynaptic differentian. Rna 20: 1–14. 
Sareen D, Ebert AD, Heins BM, McGivern J V., Ornelas L, Svendsen CN. 2012. Inhibition of 
apoptosis blocks human motor neuron cell death in a stem cell model of spinal muscular 
atrophy. PLoS One 7. 
Saxena S, Cabuy E, Caroni P. 2009. A role for motoneuron subtype-selective ER stress in disease 
manifestations of FALS mice. Nat Neurosci 12: 627–636. 
 54 
Schiffer D, Cordera S, Cavalla P, Migheli A. 1996. Reactive astrogliosis of the spinal cord in 
amyotrophic lateral sclerosis. In Journal of the Neurological Sciences, Vol. 139 of, pp. 27–33. 
Schrank B, Götz R, Gunnersen JM, Ure JM, Toyka K V, Smith AG, Sendtner M. 1997. Inactivation 
of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads 
to massive cell death in early mouse embryos. Proc Natl Acad Sci U S A 94: 9920–5. 
Sharma A, Lyashchenko AK, Lu L, Nasrabady SE, Elmaleh M, Mendelsohn M, Nemes A, Tapia 
JC, Mentis GZ, Shneider NA. 2016. ALS-associated mutant FUS induces selective motor 
neuron degeneration through toxic gain of function. Nat Commun 7: 10465. 
Shaw CE. 1997. Familial amyotrophic lateral sclerosis. Molecular pathology of a patient with a 
SOD1 mutation. Neurology 49: 1612–6. 
Silva D, Dikkes P, Barnes M, Lopez MF. 2009. Decreased motoneuron survival in Igf2 null mice 
after sciatic nerve transection. Neuroreport 20: 1414–1418. 
Singh RN, Howell MD, Ottesen EW, Singh NN. 2017. Diverse role of survival motor neuron 
protein. Biochim Biophys Acta - Gene Regul Mech 1860: 299–315. 
Southam KA, King AE, Blizzard CA, McCormack GH, Dickson TC. 2013. Microfluidic primary 
culture model of the lower motor neuron-neuromuscular junction circuit. J Neurosci Methods 
218: 164–169. 
Spiller KJ, Cheung CJ, Restrepo CR, Kwong LK, Stieber AM, Trojanowski JQ, Lee VM-Y. 2016. 
Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-
43 Proteinopathy. J Neurosci 36: 7707–7717. 
Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams 
KL, Buratti E, et al. 2008. TDP-43 mutations in familial and sporadic amyotrophic lateral 
sclerosis. Science 319: 1668–72. 
Staropoli JF, Li H, Chun SJ, Allaire N, Cullen P, Thai A, Fleet CM, Hua Y, Bennett CF, Krainer 
AR, et al. 2015. Rescue of gene-expression changes in an induced mouse model of spinal 
muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7. 
Genomics 105: 220–228. 
Sun S, Ling S-C, Qiu J, Albuquerque CP, Zhou Y, Tokunaga S, Li H, Qiu H, Bui A, Yeo GW, et al. 
2015. ALS-causative mutations in FUS/TLS confer gain and loss of function by altered 
association with SMN and U1-snRNP. Nat Commun 6: 6171. 
Taylor JE, Thomas NH, Lewis CM, Abbs SJ, Rodrigues NR, Davies KE, Mathew CG. 1998. 
Correlation of SMNt and SMNc gene copy number with age of onset and survival in spinal 
muscular atrophy. Eur J Hum Genet 6: 467–474. 
Taylor JP, Brown RH, Cleveland DW. 2016. Decoding ALS: from genes to mechanism. Nature 
539: 197–206. 
Tejero R, Lopez-Manzaneda M, Arumugam S, Tabares L. 2016. Synaptotagmin-2, and -1, linked to 
neurotransmission impairment and vulnerability in Spinal Muscular Atrophy. Hum Mol Genet. 
Tenreiro S, Munder MC, Alberti S, Outeiro TF. 2013. Harnessing the power of yeast to unravel the 
molecular basis of neurodegeneration. J Neurochem 127: 438–452. 
Tjust AE, Brannstrom T, Pedrosa Dommellof F. 2012. Unaffected motor endplate occupancy in eye 
muscle ALS G93A mouse model. Front Biosci 4: 1547–1555. 
Tollervey JR, Curk T, Rogelj B, Briese M, Cereda M, Kayikci M, Konig J, Hortobagyi T, 
Nishimura AL, Zupunski V, et al. 2011. Characterizing the RNA targets and position-
dependent splicing regulation by TDP-43. Nat Neurosci 14: 452–458. 
Torres-Torrelo J, Rodriguez-Rosell D, Nunez-Abades P, Carrascal L, Torres B. 2012. Glutamate 
modulates the firing rate in oculomotor nucleus motoneurons as a function of the recruitment 
threshold current. J Physiol 590: 3113–3127. 
Trias E, Ibarburu S, Barreto-Núñez R, Babdor J, Maciel TT, Guillo M, Gros L, Dubreuil P, Díaz-
Amarilla P, Cassina P, et al. 2016. Post-paralysis tyrosine kinase inhibition with masitinib 
abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral 
sclerosis. J Neuroinflammation 13: 177. 
Turner MR, Bowser R, Bruijn L, Dupuis L, Ludolph A, McGrath M, Manfredi G, Maragakis N, 
Miller RG, Pullman SL, et al. 2013. Mechanisms, models and biomarkers in amyotrophic 
lateral sclerosis. Amyotroph Lateral Scler Front Degener 14: 19–32. 
Valdez G, Tapia JC, Lichtman JW, Fox MA, Sanes JR. 2012. Shared resistance to aging and als in 
neuromuscular junctions of specific muscles. PLoS One 7. 
Van Damme P, Bogaert E, Dewil M, Hersmus N, Kiraly D, Scheveneels W, Bockx I, Braeken D, 
  55 
Verpoorten N, Verhoeven K, et al. 2007. Astrocytes regulate GluR2 expression in motor 
neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci 104: 14825–14830. 
Vance C, Rogelj B, Hortobágyi T, De Vos KJ, Nishimura AL, Sreedharan J, Hu X, Smith B, Ruddy 
D, Wright P, et al. 2009. Mutations in FUS, an RNA processing protein, cause familial 
amyotrophic lateral sclerosis type 6. Science 323: 1208–11. 
Verhaagen J, Oesteicher  a B, Edwards PM, Veldman H, Jennekens FG, Gispen WH. 1988. Light- 
and electron-microscopical study of phosphoprotein B-50 following denervation and 
reinnervation of the rat soleus muscle. J Neurosci 8: 1759–66. 
Waite AJ, Bäumer D, East S, Neal J, Morris HR, Ansorge O, Blake DJ. 2014. Reduced C9orf72 
protein levels in frontal cortex of amyotrophic lateral sclerosis and frontotemporal 
degeneration brain with the C9ORF72 hexanucleotide repeat expansion. Neurobiol Aging 35. 
Walker AK, Spiller KJ, Ge G, Zheng A, Xu Y, Zhou M, Tripathy K, Kwong LK, Trojanowski JQ, 
Lee VM-Y. 2015. Functional recovery in new mouse models of ALS/FTLD after clearance of 
pathological cytoplasmic TDP-43. Acta Neuropathol 130: 643–660. 
Wan L, Battle DJ, Yong J, Gubitz AK, Kolb SJ, Wang J, Dreyfuss G. 2005. The survival of motor 
neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal 
muscular atrophy. Mol Cell Biol 25: 5543–51. 
Won S-Y, Park M-H, You S-T, Choi S-W, Kim H-K, McLean C, Bae S-C, Kim SR, Jin BK, Lee 
KH, et al. 2016. Nigral dopaminergic PAK4 prevents neurodegeneration in rat models of 
Parkinson’s disease. Sci Transl Med 8: 367ra170. 
Wong M, Martin LJ. 2010. Skeletal muscle-restricted expression of human SOD1 causes motor 
neuron degeneration in transgenic mice. Hum Mol Genet 19: 2284–2302. 
Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, 
Misawa H, Cleveland DW. 2008. Astrocytes as determinants of disease progression in 
inherited amyotrophic lateral sclerosis. Nat Neurosci 11: 251–3. 
Yang YM, Gupta SK, Kim KJ, Powers BE, Cerqueira A, Wainger BJ, Ngo HD, Rosowski KA, 
Schein PA, Ackeifi CA, et al. 2013. A small molecule screen in stem-cell-derived motor 
neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12: 
713–726. 
Yoon KA, Nakamura Y, Arakawa H. 2004. Identification of ALDH4 as a p53-inducible gene and 
its protective role in cellular stresses. J Hum Genet 49: 134–140. 
Young LM, Marzio A, Perez-Duran P, Reid DA, Meredith DN, Roberti D, Star A, Rothenberg E, 
Ueberheide B, Pagano M. 2015. TIMELESS Forms a Complex with PARP1 Distinct from Its 
Complex with TIPIN and Plays a Role in the DNA Damage Response. Cell Rep 13: 451–459. 
Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, 
Cunningham KM, Vidensky S, et al. 2015. The C9orf72 repeat expansion disrupts 
nucleocytoplasmic transport. Nature 525: 56–61. 
Zhang Y, Roslan R, Lang D, Schachner M, Lieberman  a R, Anderson PN. 2000. Expression of 
CHL1 and L1 by neurons and glia following sciatic nerve and dorsal root injury. Mol Cell 
Neurosci 16: 71–86. 
Zhang Z, Lotti F, Dittmar K, Younis I, Wan L, Kasim M, Dreyfuss G. 2008. SMN Deficiency 
Causes Tissue-Specific Perturbations in the Repertoire of snRNAs and Widespread Defects in 
Splicing. Cell 133: 585–600. 
Zhang Z, Pinto AM, Wan L, Wang W, Berg MG, Oliva I, Singh LN, Dengler C, Wei Z, Dreyfuss 
G. 2013. Dysregulation of synaptogenesis genes antecedes motor neuron pathology in spinal 
muscular atrophy. Proc Natl Acad Sci U S A 110: 19348–53. 
Zhao DY, Gish G, Braunschweig U, Li Y, Ni Z, Schmitges FW, Zhong G, Liu K, Li W, Moffat J, et 
al. 2015. SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal 
domain control termination. Nature 529: 48–53. 
Zhao W, Beers DR, Appel SH. 2013. Immune-mediated mechanisms in the pathoprogression of 
amyotrophic lateral sclerosis. J Neuroimmune Pharmacol 8. 
Zhou C, Feng Z, Ko C-P. 2016. Defects in Motoneuron-Astrocyte Interactions in Spinal Muscular 
Atrophy. J Neurosci 36: 2543–2553. 
